<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cystic Fibrosis - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Cystic Fibrosis</span>
        </nav>

        <header class="page-header">
            <h1>Cystic Fibrosis</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Genetic</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0009061" target="_blank">
                        MONDO:0009061
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Respiratory Disease</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Inborn Error of Metabolism</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Cystic fibrosis is a common life-limiting autosomal recessive genetic disorder caused by mutations in the CFTR gene encoding the cystic fibrosis transmembrane conductance regulator, a chloride and bicarbonate channel expressed in epithelial cells. CFTR dysfunction leads to dehydrated, viscous secretions in multiple organ systems, most critically the airways and pancreas. Nearly 2,000 CFTR variants have been identified, with the Phe508del (F508del) mutation present in nearly 90% of patients. The disease is characterized by progressive bronchiectasis, chronic bacterial lung infection, exocrine pancreatic insufficiency, male infertility due to congenital bilateral absence of the vas deferens, and elevated sweat chloride. Multidisciplinary care and CFTR modulator therapies have extended median survival beyond 40 years, with the advent of elexacaftor-tezacaftor-ivacaftor (Trikafta) representing a transformational advance for the majority of patients.
            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <a class="stat-link" href="#definitions">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Definitions</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#inheritance">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Inheritance</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">19</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">26</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">13</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">12</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <a class="stat-link" href="#trials">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Trials</div>
            </div>
            </a>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">respiratory system disorder</span>
                    
                    <span class="tag tag-classification">hereditary disease</span>
                    
                </div>
            </div>
            
            
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        
        <div class="card" id="definitions">
            <div class="card-header">
                <div class="card-icon" style="background: #cffafe; color: #0e7490;">üìò</div>
                <h2 class="card-title">Definitions</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box definition-box">
                <div class="item-name">CF Foundation Diagnostic Criteria (2017)</div>
                
                <div class="item-desc">Consensus guidelines from the Cystic Fibrosis Foundation for establishing a diagnosis of CF in individuals from newborn to adult, requiring evidence of CFTR dysfunction via sweat chloride testing combined with clinical features or two disease-causing CFTR mutations.</div>
                
                <div class="item-meta">
                    
                    <span class="tag tag-classification">CASE_DEFINITION</span>
                    
                    
                    <span class="tag tag-parent">Diagnosis of cystic fibrosis in all age groups</span>
                    
                </div>
                
    
    
                
    
    
                
    
    
                
    
    
                
    
    
                
    
    
                
                
                <div class="criteria-block">
                    <div class="criteria-title">Diagnostic criteria for cystic fibrosis</div>
                    
                    <div class="item-desc">CF diagnosis requires clinical features consistent with CF in at least one organ system OR positive newborn screen, PLUS evidence of CFTR dysfunction demonstrated by elevated sweat chloride (&gt;=60 mmol/L) or identification of two CF-causing CFTR mutations.</div>
                    
                    
                    
    
    <div class="criteria-group">
        <div class="criteria-header">Core clinical characteristics</div>
        <ul class="criteria-list">
            
            <li>
                <span class="criteria-term">Elevated sweat chloride</span>
                
            </li>
            
            <li>
                <span class="criteria-term">Recurrent respiratory infections</span>
                
            </li>
            
            <li>
                <span class="criteria-term">Exocrine pancreatic insufficiency</span>
                
            </li>
            
            <li>
                <span class="criteria-term">Male infertility</span>
                
            </li>
            
            <li>
                <span class="criteria-term">Meconium ileus</span>
                
            </li>
            
        </ul>
    </div>
    
    
                    
    
    
                    
    
    
                    
    
    
                    
    
    
                    
    
    
                    
    
    
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28129811" target="_blank">PMID:28129811</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"It is recommended that diagnoses associated with CFTR mutations in all individuals, from newborn to adult, be established by evaluation of CFTR function with a sweat chloride test."</div>
                
                
                <div class="evidence-explanation">CF Foundation consensus guidelines establish sweat chloride testing as the cornerstone of CF diagnosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                
            </div>
            
            <div class="item-box definition-box">
                <div class="item-name">Newborn Screening Algorithm</div>
                
                <div class="item-desc">Most CF cases in the US and many other countries are identified through newborn screening (NBS) programs that measure immunoreactive trypsinogen (IRT) in dried blood spots, followed by CFTR mutation panel or a second IRT measurement. Positive screens require diagnostic confirmation with sweat chloride testing.</div>
                
                <div class="item-meta">
                    
                    <span class="tag tag-classification">DIAGNOSTIC_CRITERIA</span>
                    
                    
                    <span class="tag tag-parent">Newborn screening for cystic fibrosis</span>
                    
                </div>
                
    
    
                
    
    
                
    
    
                
    
    
                
    
    
                
    
    
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Most cases of CF are identified through newborn screening (NBS)."</div>
                
                
                <div class="evidence-explanation">Clinical review confirms newborn screening as the primary route to CF diagnosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                
            </div>
            
        </div>
        

        <!-- Inheritance -->
        
        <div class="card" id="inheritance">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #92400e;">üë™</div>
                <h2 class="card-title">Inheritance</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box inheritance-box">
                <div class="item-name">
                    Autosomal Recessive
                    
                </div>
                
                
    
    
    
    
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cystic fibrosis (CF) is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial airway infection."</div>
                
                
                <div class="evidence-explanation">Clinical review confirms autosomal recessive inheritance pattern.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">12</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
                
                
                
            
                
                
                
            
                
                
                
            
                
                
                
            
                
                
                    
                
                
            
                
                
                
            
                
                
                
            
                
                
                    
                
                
            
                
                
                
            
                
                
                
            
            
                
                <div class="classification-header">mutation class</div>
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Class I - No Protein Production
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Nonsense mutations, frameshift mutations, and canonical splice site mutations that result in premature termination codons and no functional CFTR protein production due to mRNA degradation via nonsense-mediated decay. Examples include G542X, W1282X, R553X, and 621+1G&gt;T. Class I mutations cause severe disease with pancreatic insufficiency.</div>
                    
                    
                    <ul class="subtype-children">
                        
                        <li>G542X</li>
                        
                        <li>W1282X</li>
                        
                        <li>R553X</li>
                        
                    </ul>
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27053340" target="_blank">PMID:27053340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"An effective, although not yet entirely corrective, treatment is available for patients with class III mutations, and a treatment with modest effectiveness is available for patients who are homozygous for Phe508del, albeit at a very high cost."</div>
                
                
                <div class="evidence-explanation">Review discusses CFTR mutation classes and their therapeutic implications, establishing the classification system.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Class II - Processing/Trafficking Defect
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Mutations causing CFTR protein misfolding, endoplasmic reticulum retention, and proteasomal degradation. The most important example is F508del, present in nearly 90% of CF patients. Misfolded protein is recognized by ER quality control and targeted for ubiquitin-proteasome degradation, resulting in minimal CFTR at the cell surface. Corrector drugs (lumacaftor, tezacaftor, elexacaftor) partially rescue F508del trafficking.</div>
                    
                    
                    <ul class="subtype-children">
                        
                        <li>F508del</li>
                        
                        <li>N1303K</li>
                        
                        <li>I507del</li>
                        
                    </ul>
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31697873" target="_blank">PMID:31697873</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"nearly 90% of patients have at least one copy of the Phe508del CFTR mutation"</div>
                
                
                <div class="evidence-explanation">Confirms the high prevalence of the prototypical Class II mutation F508del.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Class III - Gating Defect
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">CFTR protein reaches the cell surface normally but channel gating is severely impaired, resulting in very low open probability. The prototypical example is G551D. Potentiator drugs (ivacaftor) increase channel open probability and produce dramatic clinical benefit.</div>
                    
                    
                    <ul class="subtype-children">
                        
                        <li>G551D</li>
                        
                        <li>S549N</li>
                        
                        <li>G1244E</li>
                        
                    </ul>
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22047557" target="_blank">PMID:22047557</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The change from baseline through week 24 in the percent of predicted FEV(1) was greater by 10.6 percentage points in the ivacaftor group than in the placebo group (P&lt;0.001)."</div>
                
                
                <div class="evidence-explanation">Ivacaftor trial in G551D patients demonstrates therapeutic targeting of gating mutations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Class IV - Conductance Defect
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">CFTR reaches the cell surface and channel opens, but chloride conductance through the channel pore is reduced. Typically associated with milder phenotype and pancreatic sufficiency. Examples include R117H, R334W, and R347P.</div>
                    
                    
                    <ul class="subtype-children">
                        
                        <li>R117H</li>
                        
                        <li>R334W</li>
                        
                        <li>R347P</li>
                        
                    </ul>
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27053340" target="_blank">PMID:27053340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"An effective, although not yet entirely corrective, treatment is available for patients with class III mutations, and a treatment with modest effectiveness is available for patients who are homozygous for Phe508del, albeit at a very high cost."</div>
                
                
                <div class="evidence-explanation">Review describes mutation class-specific treatments, including Class IV conductance defects.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Class V - Reduced Quantity
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Mutations that reduce the amount of normal CFTR protein produced, such as alternative splice site mutations that produce some normal transcript alongside aberrant transcript. Typically associated with milder phenotype and pancreatic sufficiency. Examples include 3849+10kbC&gt;T and A455E.</div>
                    
                    
                    <ul class="subtype-children">
                        
                        <li>3849+10kbC&gt;T</li>
                        
                        <li>A455E</li>
                        
                    </ul>
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27053340" target="_blank">PMID:27053340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"An effective, although not yet entirely corrective, treatment is available for patients with class III mutations, and a treatment with modest effectiveness is available for patients who are homozygous for Phe508del, albeit at a very high cost."</div>
                
                
                <div class="evidence-explanation">Review discusses the classification system and mutation classes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Class VI - Decreased Stability
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">CFTR protein reaches the cell surface and functions but has accelerated turnover and reduced plasma membrane stability. Rescued F508del protein (after corrector therapy) exhibits this additional defect, necessitating combination therapy with correctors and potentiators.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37699417" target="_blank">PMID:37699417</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"With the 2019 breakthrough in the development of highly effective modulator therapy providing unprecedented clinical benefits for over 90% of patients with cystic fibrosis who are genetically eligible for treatment, this rare disease has become a front runner of transformative molecular therapy."</div>
                
                
                <div class="evidence-explanation">Review discusses CFTR modulator therapy addressing multiple defects including decreased stability.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
            
                
                <div class="classification-header">clinical phenotype</div>
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Classic Cystic Fibrosis
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Severe disease phenotype with two severe CFTR mutations, pancreatic insufficiency, progressive bronchiectasis, elevated sweat chloride (&gt;=60 mmol/L), and male infertility due to CBAVD. Represents the majority of CF patients.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cystic fibrosis (CF) is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial airway infection."</div>
                
                
                <div class="evidence-explanation">Clinical review describes the classic CF phenotype of pancreatic insufficiency and chronic airway infection.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Atypical (Non-Classic) Cystic Fibrosis
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Milder disease phenotype, often with at least one CFTR mutation conferring residual function (Class IV, V). May present with pancreatic sufficiency, milder lung disease, borderline or normal sweat chloride, and later age of diagnosis. Some patients are not diagnosed until adulthood.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33178516" target="_blank">PMID:33178516</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cystic fibrosis (CF) is an autosomal recessive, multi-organ disorder found predominantly among Caucasians."</div>
                
                
                <div class="evidence-explanation">Case report of atypical CF diagnosis at age 57, illustrating the spectrum of disease severity and late diagnosis in non-classic presentations.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"There are also infants with positive NBS but inconclusive diagnostic testing; a small proportion of these infants may go on to develop CF."</div>
                
                
                <div class="evidence-explanation">Some individuals with inconclusive diagnostic testing have milder, atypical presentations that may evolve over time.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        CFTR-Related Metabolic Syndrome (CRMS) / CF Screen Positive Inconclusive Diagnosis (CFSPID)
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Designation for infants identified by newborn screening who do not meet diagnostic criteria for CF but have some evidence of CFTR dysfunction. Defined as either intermediate sweat chloride (30-59 mmol/L) with fewer than two CF-causing CFTR mutations, or normal sweat chloride (&lt;30 mmol/L) with two CFTR mutations of which at least one has unclear clinical significance. A small proportion may evolve to a CF diagnosis over time. Requires longitudinal monitoring.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"There are also infants with positive NBS but inconclusive diagnostic testing; a small proportion of these infants may go on to develop CF."</div>
                
                
                <div class="evidence-explanation">Clinical review describes the scenario of inconclusive CF diagnosis after positive newborn screening.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28129811" target="_blank">PMID:28129811</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cystic fibrosis (CF), caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, continues to present diagnostic challenges."</div>
                
                
                <div class="evidence-explanation">CF Foundation guidelines address diagnostic challenges including CRMS/CFSPID designation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
            
                
                <div class="classification-header">CFTR related disorder</div>
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Congenital Bilateral Absence of the Vas Deferens (CBAVD)
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Isolated congenital bilateral absence of the vas deferens causing obstructive azoospermia and male infertility, without other features of classic CF. Found in approximately 1-2% of infertile males. Most affected men carry at least one CFTR mutation, often including the 5T poly-T variant or R117H. Sweat chloride is typically normal or borderline. Lung and pancreatic function are preserved.</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        CFTR-Related Pancreatitis
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Recurrent acute or chronic pancreatitis in individuals carrying one or two CFTR mutations with residual function, without meeting diagnostic criteria for CF. CFTR dysfunction impairs bicarbonate secretion in pancreatic ducts, predisposing to ductal obstruction and pancreatitis. Sweat chloride is typically normal or borderline.</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        CFTR-Related Disseminated Bronchiectasis
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Diffuse bronchiectasis in individuals carrying CFTR mutations who do not meet diagnostic criteria for CF. Sweat chloride may be normal or borderline. Represents the milder end of the CFTR dysfunction spectrum affecting the airways.</div>
                    
                    
                    
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">19</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">CFTR Dysfunction</div>
                
                <div class="item-desc">Mutations in the CFTR gene cause defective chloride and bicarbonate channel function. CFTR is a unique member of the ABC transporter family located predominantly in the apical membrane of epithelia where it mediates transepithelial salt and liquid movement. Loss of CFTR function leads to impaired chloride and bicarbonate secretion across epithelial surfaces in the airways, pancreas, intestine, hepatobiliary system, sweat glands, and reproductive tract, resulting in dehydrated, acidic secretions.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Epithelial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000066" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Chloride Transport
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006821" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Ion Transport
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006811" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/9922375" target="_blank">PMID:9922375</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The cystic fibrosis transmembrane conductance regulator (CFTR) is a unique member of the ABC transporter family that forms a novel Cl- channel. It is located predominantly in the apical membrane of epithelia where it mediates transepithelial salt and liquid movement. Dysfunction of CFTR causes..."</div>
                
                
                <div class="evidence-explanation">Comprehensive review establishes CFTR as chloride channel whose dysfunction causes cystic fibrosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/9922375" target="_blank">PMID:9922375</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The CFTR is composed of five domains: two membrane-spanning domains (MSDs), two nucleotide-binding domains (NBDs), and a regulatory (R) domain."</div>
                
                
                <div class="evidence-explanation">Describes the five-domain architecture of CFTR critical to understanding mutation effects.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Airway Surface Liquid Depletion</div>
                
                <div class="item-desc">Loss of CFTR-mediated chloride and bicarbonate secretion on airway epithelial surfaces depletes the periciliary liquid layer and airway surface liquid (ASL). Concurrent sodium hyperabsorption via ENaC further dehydrates the airway surface. The depleted ASL impairs mucociliary clearance by collapsing cilia and tethering mucus to the epithelial surface, initiating the cycle of mucus obstruction and infection.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Bronchial epithelial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002328" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Mucus Secretion
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0070254" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Lung
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002048" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23878362" target="_blank">PMID:23878362</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"CF lungs are characterized by viscous, dehydrated mucus, persistent neutrophilia and chronic infections. ENaC is negatively regulated by CFTR and, in patients with CF, the absence of CFTR results in a double hit of reduced Cl-/HCO3- and H2O secretion as well as ENaC hyperactivity and increased..."</div>
                
                
                <div class="evidence-explanation">Review describes ENaC hyperactivity and dehydration mechanism in CF airways.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Mucus Plugging and Airway Obstruction</div>
                
                <div class="item-desc">Defective CFTR leads to depleted airway surface liquid and thick mucus. Impaired mucociliary clearance creates mucus plugs in small and medium airways, causing airflow obstruction and air trapping. The stagnant mucus forms an anaerobic niche that favors bacterial colonization and biofilm formation.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Bronchial epithelial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002328" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Mucus Secretion
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0070254" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22711878" target="_blank">PMID:22711878</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype."</div>
                
                
                <div class="evidence-explanation">Study demonstrates the mechanistic link between CFTR dysfunction and abnormal mucus properties.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Chronic Bacterial Infection</div>
                
                <div class="item-desc">The CF airway is chronically colonized by characteristic pathogens. Staphylococcus aureus typically predominates in early childhood, followed by Pseudomonas aeruginosa which becomes the dominant pathogen in adolescence and adulthood. P. aeruginosa transitions to a mucoid phenotype with alginate biofilm production, making eradication extremely difficult. Other important pathogens include Burkholderia cepacia complex, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and non-tuberculous mycobacteria.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Defense response to bacterium
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0042742" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cystic fibrosis (CF) is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial airway infection."</div>
                
                
                <div class="evidence-explanation">Clinical review identifies chronic endobronchial infection as a defining characteristic of CF.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Neutrophilic Airway Inflammation</div>
                
                <div class="item-desc">The CF airway is characterized by an exaggerated and sustained neutrophilic inflammatory response. Massive neutrophil influx releases proteases (especially neutrophil elastase), oxidants, and extracellular DNA that further damage the airway epithelium, impair mucociliary clearance, and perpetuate the vicious cycle of infection and inflammation. Neutrophil elastase overwhelms antiprotease defenses and directly damages airway tissue. The resulting free DNA from necrotic neutrophils further increases mucus viscosity.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Neutrophil
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000775" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Inflammatory response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29258516" target="_blank">PMID:29258516</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The role of neutrophil elastase (NE) is poorly understood in bronchiectasis because of the lack of preclinical data and so most of the assumptions made about NE inhibitor potential benefit is based on data from CF."</div>
                
                
                <div class="evidence-explanation">Review confirms neutrophil elastase as a key marker of inflammation in CF and bronchiectasis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Bronchiectasis and Airway Remodeling</div>
                
                <div class="item-desc">The vicious cycle of mucus obstruction, chronic infection, and neutrophilic inflammation causes progressive, irreversible bronchiectasis. Airway walls become thickened, dilated, and scarred. Ongoing proteolytic damage from neutrophil elastase and matrix metalloproteinases destroys cartilage and elastic tissue. Progressive bronchiectasis leads to respiratory failure, which is the leading cause of death in CF.</div>
                
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Lung
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002048" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This latter feature results in progressive bronchiectasis and ultimately respiratory failure, which is the leading cause of death in patients with CF."</div>
                
                
                <div class="evidence-explanation">Clinical review confirms progressive bronchiectasis leading to respiratory failure as the primary cause of mortality.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Respiratory Failure</div>
                
                <div class="item-desc">End-stage CF lung disease results in progressive respiratory failure with hypoxemia, hypercapnia, and cor pulmonale. Respiratory failure is the leading cause of death in CF patients and the primary indication for lung transplantation.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This latter feature results in progressive bronchiectasis and ultimately respiratory failure, which is the leading cause of death in patients with CF."</div>
                
                
                <div class="evidence-explanation">Respiratory failure is confirmed as the leading cause of CF mortality.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Pancreatic Duct Obstruction</div>
                
                <div class="item-desc">CFTR dysfunction in pancreatic ductal epithelium impairs bicarbonate and fluid secretion, leading to viscid secretions that obstruct pancreatic ducts. The resulting ductal obstruction causes premature activation of digestive enzymes, autodigestion, acinar cell destruction, and progressive fibrosis. In utero pancreatic damage begins in the second trimester in severely affected individuals, and pancreatic insufficiency is present at birth in most patients with two severe CFTR mutations.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Pancreatic ductal cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002079" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        Pancreatic acinar cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002064" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Pancreas
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001264" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Pediatric review confirms pancreatic insufficiency and dysfunction as core CF manifestations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Exocrine Pancreatic Insufficiency</div>
                
                <div class="item-desc">Destruction of exocrine pancreatic tissue causes insufficient production of digestive enzymes including lipase, amylase, and proteases. Present in 85-90% of CF patients, pancreatic insufficiency causes fat and protein malabsorption leading to steatorrhea, failure to thrive, and fat-soluble vitamin deficiency (vitamins A, D, E, K). Pancreatic sufficiency is more common in patients with at least one mild (class IV-V) CFTR mutation.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cystic fibrosis (CF) is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial airway infection."</div>
                
                
                <div class="evidence-explanation">Clinical review identifies pancreatic insufficiency as a defining characteristic of cystic fibrosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Fat Malabsorption</div>
                
                <div class="item-desc">Insufficient pancreatic lipase causes malabsorption of dietary fat, resulting in steatorrhea (fatty, bulky, foul-smelling stools), caloric loss, and deficiency of fat-soluble vitamins. Fat malabsorption is a major contributor to malnutrition and failure to thrive in CF.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Pediatric review confirms malabsorption as a clinical characteristic of CF.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Fat-Soluble Vitamin Deficiency</div>
                
                <div class="item-desc">Malabsorption of fat-soluble vitamins A, D, E, and K leads to specific deficiency states. Vitamin A deficiency can cause night blindness, vitamin D deficiency contributes to CF bone disease, vitamin E deficiency may cause neurological symptoms, and vitamin K deficiency increases bleeding risk.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Malabsorption leads to vitamin deficiencies as part of the CF nutritional phenotype.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Protein-Calorie Malnutrition</div>
                
                <div class="item-desc">Combined effects of pancreatic insufficiency, increased metabolic demands from chronic infection and inflammation, and poor appetite lead to protein-calorie malnutrition, failure to thrive in children, and poor weight maintenance in adults. Nutritional status is strongly correlated with lung function and survival.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33178516" target="_blank">PMID:33178516</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"It classically presents in childhood with chronic productive cough, malabsorption causing steatorrhea, and failure to thrive."</div>
                
                
                <div class="evidence-explanation">Case report review confirms malabsorption and failure to thrive as classic CF presentations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">CF-Related Diabetes</div>
                
                <div class="item-desc">Progressive fibrosis and fatty infiltration of the pancreas destroys islets of Langerhans, reducing insulin secretion capacity. CF-related diabetes (CFRD) is distinct from type 1 and type 2 diabetes, characterized primarily by insulin insufficiency with variable insulin resistance, especially during pulmonary exacerbations. CFRD affects up to 50% of adult CF patients and is associated with accelerated decline in lung function and increased mortality if untreated.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Pancreatic beta cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000169" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Pancreas
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001264" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility."</div>
                
                
                <div class="evidence-explanation">Clinical review lists diabetes mellitus among established complications of CF.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Intestinal Obstruction</div>
                
                <div class="item-desc">Dehydrated intestinal secretions cause bowel obstruction at different ages. Meconium ileus occurs in 15-20% of CF neonates due to inspissated meconium in the distal ileum. In older children and adults, distal intestinal obstruction syndrome (DIOS) presents with similar pathophysiology in the ileocecal region. Constipation is also common due to dehydrated intestinal contents.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility."</div>
                
                
                <div class="evidence-explanation">Clinical review lists bowel obstruction among established complications of CF.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Hepatobiliary Obstruction</div>
                
                <div class="item-desc">CFTR dysfunction in cholangiocytes causes viscid bile secretions that obstruct intrahepatic bile ductules. This leads to focal biliary cirrhosis, which can progress to multilobular cirrhosis with portal hypertension in 5-10% of CF patients. CF liver disease is the third leading cause of death after respiratory failure and transplant complications.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Cholangiocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_1000488" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Liver
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002107" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility."</div>
                
                
                <div class="evidence-explanation">Clinical review lists hepatobiliary disease among established complications of CF.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Sweat Gland Dysfunction</div>
                
                <div class="item-desc">In sweat glands, CFTR is required for chloride reabsorption in the sweat duct. Loss of CFTR function results in failure to reabsorb chloride from primary sweat, producing sweat with elevated chloride concentration. This is the basis of the diagnostic sweat chloride test. Excessive salt loss can cause hyponatremic dehydration, especially in hot weather or during exercise.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Diagnosis of CF is confirmed by demonstration of elevated sweat chloride."</div>
                
                
                <div class="evidence-explanation">Elevated sweat chloride reflects defective CFTR-mediated chloride reabsorption in sweat ducts.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Vas Deferens Agenesis</div>
                
                <div class="item-desc">CFTR is required for normal development of the Wolffian duct derivatives. Congenital bilateral absence of the vas deferens (CBAVD) occurs in approximately 97-98% of males with CF due to inspissation and atresia of the vas deferens during fetal development. CBAVD causes obstructive azoospermia and male infertility. Notably, CBAVD can occur as an isolated finding in males who carry one or two CFTR mutations with residual function, representing a CFTR-related disorder.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility."</div>
                
                
                <div class="evidence-explanation">Clinical review confirms infertility as an established complication of CF.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Sinonasal Disease</div>
                
                <div class="item-desc">CFTR dysfunction in the sinonasal epithelium causes mucus retention and chronic inflammation in the paranasal sinuses. Chronic rhinosinusitis affects nearly all CF patients. Nasal polyposis occurs in 10-32% of CF patients and is unusual in children without CF, making it an important diagnostic clue.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility."</div>
                
                
                <div class="evidence-explanation">Clinical review lists sinusitis among established complications of CF.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">CF Bone Disease</div>
                
                <div class="item-desc">CF-related bone disease results from multiple converging mechanisms including vitamin D deficiency from fat malabsorption, chronic systemic inflammation with elevated cytokines (IL-6, TNF-alpha) that promote osteoclast activity, reduced physical activity, delayed puberty with reduced sex steroids, glucocorticoid use, and possibly direct CFTR effects on osteoblast function. Osteopenia and osteoporosis are common in adults with CF.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Malnutrition from pancreatic insufficiency contributes to bone disease in CF patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Intestinal_Obstruction[&#34;Intestinal Obstruction&#34;]
    Fat_Soluble_Vitamin_Deficiency[&#34;Fat-Soluble Vitamin Deficiency&#34;]
    Hepatobiliary_Obstruction[&#34;Hepatobiliary Obstruction&#34;]
    Neutrophilic_Airway_Inflammation[&#34;Neutrophilic Airway Inflammation&#34;]
    Airway_Surface_Liquid_Depletion[&#34;Airway Surface Liquid Depletion&#34;]
    Sweat_Gland_Dysfunction[&#34;Sweat Gland Dysfunction&#34;]
    CF_Related_Diabetes[&#34;CF-Related Diabetes&#34;]
    Pancreatic_Duct_Obstruction[&#34;Pancreatic Duct Obstruction&#34;]
    CFTR_Dysfunction[&#34;CFTR Dysfunction&#34;]
    Protein_Calorie_Malnutrition[&#34;Protein-Calorie Malnutrition&#34;]
    Respiratory_Failure[&#34;Respiratory Failure&#34;]
    Bronchiectasis_and_Airway_Remodeling[&#34;Bronchiectasis and Airway Remodeling&#34;]
    Exocrine_Pancreatic_Insufficiency[&#34;Exocrine Pancreatic Insufficiency&#34;]
    Vas_Deferens_Agenesis[&#34;Vas Deferens Agenesis&#34;]
    Mucus_Plugging_and_Airway_Obstruction[&#34;Mucus Plugging and Airway Obstruction&#34;]
    Chronic_Bacterial_Infection[&#34;Chronic Bacterial Infection&#34;]
    Fat_Malabsorption[&#34;Fat Malabsorption&#34;]

    CFTR_Dysfunction --&gt; Airway_Surface_Liquid_Depletion
    CFTR_Dysfunction --&gt; Pancreatic_Duct_Obstruction
    CFTR_Dysfunction --&gt; Intestinal_Obstruction
    CFTR_Dysfunction --&gt; Sweat_Gland_Dysfunction
    CFTR_Dysfunction --&gt; Vas_Deferens_Agenesis
    CFTR_Dysfunction --&gt; Hepatobiliary_Obstruction
    Airway_Surface_Liquid_Depletion --&gt; Mucus_Plugging_and_Airway_Obstruction
    Mucus_Plugging_and_Airway_Obstruction --&gt; Chronic_Bacterial_Infection
    Mucus_Plugging_and_Airway_Obstruction --&gt; Bronchiectasis_and_Airway_Remodeling
    Chronic_Bacterial_Infection --&gt; Neutrophilic_Airway_Inflammation
    Chronic_Bacterial_Infection --&gt; Bronchiectasis_and_Airway_Remodeling
    Neutrophilic_Airway_Inflammation --&gt; Bronchiectasis_and_Airway_Remodeling
    Bronchiectasis_and_Airway_Remodeling --&gt; Respiratory_Failure
    Pancreatic_Duct_Obstruction --&gt; Exocrine_Pancreatic_Insufficiency
    Pancreatic_Duct_Obstruction --&gt; CF_Related_Diabetes
    Exocrine_Pancreatic_Insufficiency --&gt; Fat_Malabsorption
    Exocrine_Pancreatic_Insufficiency --&gt; Fat_Soluble_Vitamin_Deficiency
    Exocrine_Pancreatic_Insufficiency --&gt; Protein_Calorie_Malnutrition
    Fat_Malabsorption --&gt; Fat_Soluble_Vitamin_Deficiency

    style Intestinal_Obstruction fill:#dbeafe
    style Fat_Soluble_Vitamin_Deficiency fill:#fef3c7
    style Hepatobiliary_Obstruction fill:#dbeafe
    style Neutrophilic_Airway_Inflammation fill:#dbeafe
    style Airway_Surface_Liquid_Depletion fill:#dbeafe
    style Sweat_Gland_Dysfunction fill:#dbeafe
    style CF_Related_Diabetes fill:#fef3c7
    style Pancreatic_Duct_Obstruction fill:#dbeafe
    style CFTR_Dysfunction fill:#dbeafe
    style Protein_Calorie_Malnutrition fill:#dbeafe
    style Respiratory_Failure fill:#dbeafe
    style Bronchiectasis_and_Airway_Remodeling fill:#dbeafe
    style Exocrine_Pancreatic_Insufficiency fill:#fef3c7
    style Vas_Deferens_Agenesis fill:#dbeafe
    style Mucus_Plugging_and_Airway_Obstruction fill:#dbeafe
    style Chronic_Bacterial_Infection fill:#dbeafe
    style Fat_Malabsorption fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">26</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Cardiovascular<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Digestive<span class="pill-count">(8)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Endocrine<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Genitourinary<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Head and Neck<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-6">Immune<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-7">Limbs<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-8">Metabolism<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-9">Musculoskeletal<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-10">Respiratory<span class="pill-count">(4)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-11">Growth<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-12">Other<span class="pill-count">(1)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Portal Hypertension
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001409" target="_blank">
                                Portal hypertension
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001409)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Occurs in patients who progress to multilobular cirrhosis. May require portosystemic shunting or liver transplantation.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Liver and pancreatic dysfunction in CF includes cirrhosis leading to portal hypertension.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Digestive
                    <span class="cat-count">8</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Exocrine Pancreatic Insufficiency
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001738" target="_blank">
                                Exocrine pancreatic insufficiency
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001738)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Present in 85-90% of CF patients, typically those with two severe CFTR mutations. Patients with at least one mild mutation may retain pancreatic sufficiency.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cystic fibrosis (CF) is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial airway infection."</div>
                
                
                <div class="evidence-explanation">Clinical review identifies pancreatic insufficiency as a defining characteristic of cystic fibrosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Steatorrhea
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002570" target="_blank">
                                Steatorrhea
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002570)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">A classic presenting symptom of CF in infancy and early childhood.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33178516" target="_blank">PMID:33178516</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"It classically presents in childhood with chronic productive cough, malabsorption causing steatorrhea, and failure to thrive."</div>
                
                
                <div class="evidence-explanation">Review confirms steatorrhea as a classic presentation of cystic fibrosis due to malabsorption.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Meconium Ileus
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0004401" target="_blank">
                                Meconium ileus
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0004401)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Present in 15-20% of CF newborns. May be complicated by volvulus, atresia, or perforation. Meconium ileus in a neonate is highly suggestive of CF.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility."</div>
                
                
                <div class="evidence-explanation">Clinical review lists bowel obstruction (including meconium ileus) among established complications of CF.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Distal Intestinal Obstruction Syndrome
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0005214" target="_blank">
                                Intestinal obstruction
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0005214)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Occurs in approximately 10-15% of CF patients. Risk factors include pancreatic insufficiency, dehydration, and inadequate enzyme replacement.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility."</div>
                
                
                <div class="evidence-explanation">Bowel obstruction including DIOS is an established complication in CF patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Rectal Prolapse
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002035" target="_blank">
                                Rectal prolapse
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002035)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Less common since advent of newborn screening and early treatment.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Malnutrition from pancreatic insufficiency contributes to complications like rectal prolapse.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Gastroesophageal Reflux
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002020" target="_blank">
                                Gastroesophageal reflux
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002020)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">GI complications are common in CF and include gastroesophageal reflux.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Focal Biliary Cirrhosis
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002613" target="_blank">
                                Biliary cirrhosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002613)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">CF liver disease is the third leading cause of CF mortality. Ursodeoxycholic acid may slow progression.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility."</div>
                
                
                <div class="evidence-explanation">Clinical review lists hepatobiliary disease among established complications of CF.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Fat-Soluble Vitamin Deficiency
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002024" target="_blank">
                                Malabsorption
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002024)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Routine supplementation of fat-soluble vitamins is standard of care.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Malabsorption from pancreatic insufficiency causes vitamin deficiencies.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Endocrine
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        CF-Related Diabetes
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000819" target="_blank">
                                Diabetes mellitus
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000819)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Prevalence increases with age, affecting up to 20% of adolescents and 50% of adults with CF. Annual screening with oral glucose tolerance test recommended from age 10.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility."</div>
                
                
                <div class="evidence-explanation">Clinical review lists diabetes mellitus among established complications of CF.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Delayed Puberty
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000823" target="_blank">
                                Delayed puberty
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000823)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">More common when nutritional status is poor.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Malnutrition from pancreatic insufficiency contributes to delayed puberty in CF patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Genitourinary
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Male Infertility
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003251" target="_blank">
                                Male infertility
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003251)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">CBAVD can also occur as an isolated finding in males carrying one or two CFTR mutations, representing a CFTR-related disorder.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility."</div>
                
                
                <div class="evidence-explanation">Clinical review lists infertility among the established complications of cystic fibrosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Reduced Female Fertility
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0008222" target="_blank">
                                Female infertility
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0008222)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Not absolute infertility; many CF women conceive, especially with improved health status on modulator therapy.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Reproductive complications including reduced fertility affect CF patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Head and Neck
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Nasal Polyposis
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0100582" target="_blank">
                                Nasal polyposis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0100582)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Present in 10-32% of CF patients. In children, nasal polyps are uncommon outside of CF and should trigger sweat testing.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Chronic Sinusitis
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0011109" target="_blank">
                                Chronic sinusitis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0011109)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Radiographic sinusitis is nearly universal; symptomatic disease varies.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility."</div>
                
                
                <div class="evidence-explanation">Clinical review lists sinusitis among established complications of CF.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-6">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Immune
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Recurrent Respiratory Infections
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002205" target="_blank">
                                Recurrent respiratory infections
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002205)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Chronic Pseudomonas aeruginosa and Staphylococcus aureus infections are hallmarks of CF lung disease.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cystic fibrosis (CF) is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial airway infection."</div>
                
                
                <div class="evidence-explanation">Clinical review identifies chronic airway infection as a defining characteristic of cystic fibrosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-7">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Limbs
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Digital Clubbing
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001217" target="_blank">
                                Clubbing
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001217)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Develops with progression of lung disease; correlates with severity.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Progressive obstructive lung disease leads to chronic hypoxemia and clubbing.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-8">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Metabolism
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hyponatremic Dehydration
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002902" target="_blank">
                                Hyponatremia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002902)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Can be a presenting feature in infancy. Salt supplementation is recommended.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility."</div>
                
                
                <div class="evidence-explanation">Clinical review lists hyponatremic dehydration among established complications of CF.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-9">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Musculoskeletal
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Osteoporosis
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000939" target="_blank">
                                Osteoporosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000939)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Bone density screening with DXA recommended for adults with CF.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Malnutrition and vitamin D deficiency from malabsorption contribute to osteoporosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-10">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Respiratory
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Chronic Productive Cough
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0031245" target="_blank">
                                Productive cough
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0031245)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">One of the classic presenting symptoms of CF along with steatorrhea and failure to thrive.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33178516" target="_blank">PMID:33178516</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"It classically presents in childhood with chronic productive cough, malabsorption causing steatorrhea, and failure to thrive."</div>
                
                
                <div class="evidence-explanation">Review confirms chronic productive cough as a classic presentation of cystic fibrosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Bronchiectasis
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002110" target="_blank">
                                Bronchiectasis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002110)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Progressive and eventually universal in CF patients; the primary driver of morbidity and mortality.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This latter feature results in progressive bronchiectasis and ultimately respiratory failure, which is the leading cause of death in patients with CF."</div>
                
                
                <div class="evidence-explanation">Clinical review confirms progressive bronchiectasis as a consequence of chronic airway infection in CF.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hemoptysis
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002105" target="_blank">
                                Hemoptysis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002105)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Minor hemoptysis is common; massive hemoptysis occurs in 4-5% of patients.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Progressive obstructive lung disease leads to complications including hemoptysis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Pneumothorax
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002107" target="_blank">
                                Pneumothorax
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002107)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Occurs in 3-4% of CF patients; recurrence rate is high.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Progressive obstructive lung disease is associated with complications such as pneumothorax.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-11">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Growth
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Failure to Thrive
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001508" target="_blank">
                                Failure to thrive
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001508)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">A classic presenting feature, especially before newborn screening era. Nutritional status strongly correlates with lung function and survival.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33178516" target="_blank">PMID:33178516</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"It classically presents in childhood with chronic productive cough, malabsorption causing steatorrhea, and failure to thrive."</div>
                
                
                <div class="evidence-explanation">Review confirms failure to thrive as a classic presentation of cystic fibrosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Short Stature
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0004322" target="_blank">
                                Short stature
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0004322)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Improved with optimized nutritional support and CFTR modulator therapy.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Malnutrition from pancreatic insufficiency contributes to growth failure and short stature.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-12">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Allergic Bronchopulmonary Aspergillosis
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Affects 2-15% of CF patients; requires high index of suspicion.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Progressive obstructive lung disease encompasses various complications including fungal sensitization.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CFTR
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31697873" target="_blank">PMID:31697873</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, and nearly 90% of patients have at least one copy of the Phe508del CFTR mutation."</div>
                
                
                <div class="evidence-explanation">Phase 3 trial confirms CFTR mutations cause CF and F508del is the most common mutation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23974870" target="_blank">PMID:23974870</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Few of the almost 2,000 variants in the cystic fibrosis transmembrane conductance regulator gene CFTR have empirical evidence that they cause cystic fibrosis."</div>
                
                
                <div class="evidence-explanation">CFTR2 project establishes the scope of CFTR variant heterogeneity.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23974870" target="_blank">PMID:23974870</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"we collected both genotype and phenotype data for 39,696 individuals with cystic fibrosis in registries and clinics in North America and Europe"</div>
                
                
                <div class="evidence-explanation">CFTR2 project provides the largest systematic analysis of CFTR variant-disease relationships.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">13</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Elexacaftor-Tezacaftor-Ivacaftor (Trikafta/Kaftrio)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Triple combination CFTR modulator therapy containing two correctors (elexacaftor, tezacaftor) that improve F508del-CFTR folding and trafficking to the cell surface, plus a potentiator (ivacaftor) that increases channel open probability. Approved for patients aged 2+ years with at least one F508del allele, covering approximately 90% of CF patients. Produces dramatic improvements in lung function, nutritional status, and quality of life.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31697873" target="_blank">PMID:31697873</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Elexacaftor-tezacaftor-ivacaftor, relative to placebo, resulted in a percentage of predicted FEV1 that was 13.8 points higher at 4 weeks and 14.3 points higher through 24 weeks, a rate of pulmonary exacerbations that was 63% lower"</div>
                
                
                <div class="evidence-explanation">Phase 3 RCT demonstrates significant improvement in lung function and 63% reduction in pulmonary exacerbations with Trikafta.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31697873" target="_blank">PMID:31697873</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"a respiratory domain score on the Cystic Fibrosis Questionnaire-Revised...that was 20.2 points higher, and a sweat chloride concentration that was 41.8 mmol per liter lower"</div>
                
                
                <div class="evidence-explanation">Trikafta also improves quality of life scores and reduces sweat chloride, a biomarker of CFTR function.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Ivacaftor (Kalydeco)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">CFTR potentiator that increases the channel open probability of CFTR protein at the cell surface. First approved CFTR modulator, initially for G551D mutation and subsequently expanded to other gating mutations. As monotherapy, effective only for mutations where CFTR reaches the cell surface (Class III, IV, V mutations).</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22047557" target="_blank">PMID:22047557</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The change from baseline through week 24 in the percent of predicted FEV(1) was greater by 10.6 percentage points in the ivacaftor group than in the placebo group (P&lt;0.001)."</div>
                
                
                <div class="evidence-explanation">Landmark Phase 3 trial demonstrating sustained lung function improvement with ivacaftor in G551D patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Airway Clearance Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000011" target="_blank">
                            MAXO:0000011
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Chest physiotherapy techniques to mobilize and clear airway secretions. Includes manual chest percussion and postural drainage, oscillating positive expiratory pressure devices (e.g., Flutter, Acapella), high-frequency chest wall oscillation vests, autogenic drainage, and regular exercise. Performed at least twice daily.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific..."</div>
                
                
                <div class="evidence-explanation">Evidence-based guidelines for pulmonary health include airway clearance therapies.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Dornase Alfa (Pulmozyme)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Inhaled recombinant human DNase that cleaves extracellular DNA released from necrotic neutrophils in CF sputum, reducing mucus viscosity and improving airway clearance. Recommended for daily use in most CF patients.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/8874241" target="_blank">PMID:8874241</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Dornase alfa improved the mean percent change in FEV1 from baseline by 9.4% compared with 2.1% for placebo (p &lt; 0.001)."</div>
                
                
                <div class="evidence-explanation">Randomized controlled trial demonstrates significant improvement in lung function with dornase alfa.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Hypertonic Saline (7%)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Inhaled nebulized hypertonic saline that osmotically draws water onto the airway surface, rehydrating the periciliary layer and improving mucociliary clearance. Used as adjunctive therapy to improve mucus mobilization.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific..."</div>
                
                
                <div class="evidence-explanation">Evidence-based therapies for pulmonary health include mucolytic agents like hypertonic saline.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Inhaled Antibiotics
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Chronic suppressive inhaled antibiotic therapy for patients with chronic Pseudomonas aeruginosa infection. Inhaled tobramycin (alternating months) and inhaled aztreonam lysine are most commonly used. Reduces bacterial density, decreases pulmonary exacerbations, and preserves lung function.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific..."</div>
                
                
                <div class="evidence-explanation">Improved survival reflects evidence-based treatments including inhaled antibiotics for chronic infection.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Systemic Antibiotics
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Oral and intravenous antibiotics for acute pulmonary exacerbations and chronic suppressive therapy. Azithromycin is used chronically for its anti-inflammatory and anti-Pseudomonal properties. IV antibiotic courses (typically 14-21 days) target specific pathogens identified on sputum culture.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific..."</div>
                
                
                <div class="evidence-explanation">Evidence-based care includes systemic antibiotics for treating pulmonary exacerbations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Pancreatic Enzyme Replacement Therapy (PERT)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Oral pancreatic enzyme supplements (lipase, protease, amylase) taken with all meals and snacks to replace deficient endogenous enzymes. Dosing is individualized based on fat intake and symptoms. Essential for maintaining adequate nutrition in pancreatic-insufficient patients.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific..."</div>
                
                
                <div class="evidence-explanation">Optimization of nutritional health includes pancreatic enzyme replacement therapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Nutritional Support
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">High-calorie, high-fat diet with fat-soluble vitamin supplementation (A, D, E, K) and sodium chloride supplementation. CF patients have increased caloric requirements (120-150% of normal) due to malabsorption, chronic infection, and increased work of breathing. Enteral tube feeding may be needed for patients unable to maintain adequate weight.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific..."</div>
                
                
                <div class="evidence-explanation">Evidence-based guidelines emphasize optimization of nutritional health for CF patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Insulin Therapy for CFRD
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Insulin is the recommended treatment for CF-related diabetes. Oral hypoglycemic agents are generally not recommended as primary therapy due to the predominantly insulin-deficient pathophysiology. Insulin improves nutritional status and lung function in addition to glycemic control.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility."</div>
                
                
                <div class="evidence-explanation">CF-related diabetes is an established complication requiring insulin therapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Ursodeoxycholic Acid
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Hydrophilic bile acid used to improve bile flow and potentially slow progression of CF liver disease. Commonly prescribed for patients with elevated liver enzymes or evidence of focal biliary cirrhosis, though evidence for long-term clinical benefit is limited.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility."</div>
                
                
                <div class="evidence-explanation">Hepatobiliary disease in CF is treated with agents like ursodeoxycholic acid.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Lung Transplantation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0010039" target="_blank">
                            MAXO:0010039
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Bilateral lung transplantation is offered for end-stage CF lung disease when predicted survival without transplant is limited (typically FEV1 &lt;30% predicted with rapid decline). Five-year survival after transplant is approximately 50-60%. CF lung disease does not recur in the transplanted lungs, but immunosuppression-related complications and chronic rejection (bronchiolitis obliterans syndrome) limit long-term outcomes.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This latter feature results in progressive bronchiectasis and ultimately respiratory failure, which is the leading cause of death in patients with CF."</div>
                
                
                <div class="evidence-explanation">Respiratory failure as the leading cause of death necessitates lung transplantation for end-stage disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic Counseling
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000079" target="_blank">
                            MAXO:0000079
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Counseling for patients and families regarding autosomal recessive inheritance, carrier testing for at-risk relatives, prenatal diagnosis options, and reproductive planning. Carrier frequency is approximately 1 in 25 in European-descent populations.</div>
                
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Pseudomonas aeruginosa</div>
                
                <div class="item-desc">Transition from non-mucoid to mucoid phenotype is a milestone event in CF.</div>
                
                
                <div class="item-desc">The most important pathogen in CF lung disease. Initial acquisition of non-mucoid strains progresses to chronic infection with mucoid, alginate-producing phenotypes that form antibiotic-resistant biofilms. Chronic Pseudomonas infection is associated with accelerated decline in lung function and increased mortality. Early eradication protocols aim to delay chronic colonization.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cystic fibrosis (CF) is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial airway infection."</div>
                
                
                <div class="evidence-explanation">Chronic endobronchial infection including Pseudomonas is a defining characteristic of CF.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Staphylococcus aureus</div>
                
                <div class="item-desc">Most common respiratory pathogen in young CF children.</div>
                
                
                <div class="item-desc">Often the first pathogen to colonize CF airways in infancy. Both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains are common. MRSA infection is associated with worse lung function outcomes.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Progressive obstructive lung disease is driven by chronic bacterial infections including S. aureus.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Burkholderia cepacia complex</div>
                
                <div class="item-desc">Infection control and patient segregation are critical.</div>
                
                
                <div class="item-desc">Highly virulent group of gram-negative bacteria associated with rapid and sometimes fatal decline in lung function (cepacia syndrome). Patient-to-patient transmission necessitates strict infection control measures. B. cenocepacia (genomovar III) is the most virulent species and is a relative contraindication to lung transplantation at many centers.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Progressive lung disease can be accelerated by virulent pathogens like Burkholderia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Non-tuberculous Mycobacteria</div>
                
                <div class="item-desc">Screening sputum cultures recommended annually.</div>
                
                
                <div class="item-desc">Mycobacterium abscessus complex and Mycobacterium avium complex are increasingly recognized in CF. M. abscessus is particularly concerning due to treatment resistance, potential for progressive lung disease, and may complicate lung transplant candidacy.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Progressive obstructive lung disease involves various pathogens including non-tuberculous mycobacteria.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Aspergillus fumigatus</div>
                
                <div class="item-desc">ABPA requires treatment with systemic corticosteroids and antifungal agents.</div>
                
                
                <div class="item-desc">Fungal colonization of CF airways that can trigger allergic bronchopulmonary aspergillosis (ABPA), an IgE-mediated hypersensitivity response causing worsening airflow obstruction and central bronchiectasis.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Progressive obstructive lung disease includes complications from fungal colonization.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Tobacco Smoke Exposure</div>
                
                <div class="item-desc">Strict avoidance counseling is part of standard CF care.</div>
                
                
                <div class="item-desc">Both active and passive tobacco smoke exposure accelerates lung function decline in CF patients. Environmental tobacco smoke is a significant modifiable risk factor, especially in children.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific..."</div>
                
                
                <div class="evidence-explanation">Evidence-based guidelines include avoidance of environmental risk factors like tobacco smoke.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Air Pollution</div>
                
                <div class="item-desc">Epidemiologic association; exposure minimization recommended.</div>
                
                
                <div class="item-desc">Ambient air pollution (particulate matter, ozone, nitrogen dioxide) is associated with increased pulmonary exacerbation rates and accelerated lung function decline in CF.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific..."</div>
                
                
                <div class="evidence-explanation">Optimization of pulmonary health includes minimizing environmental exposures.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Sweat Chloride
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Sweat chloride &gt;=60 mmol/L is diagnostic of CF; 30-59 mmol/L is intermediate and requires further evaluation; &lt;30 mmol/L makes CF unlikely.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Diagnosis of CF is confirmed by demonstration of elevated sweat chloride."</div>
                
                
                <div class="evidence-explanation">Elevated sweat chloride is the diagnostic hallmark of CF.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28129811" target="_blank">PMID:28129811</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"It is recommended that diagnoses associated with CFTR mutations in all individuals, from newborn to adult, be established by evaluation of CFTR function with a sweat chloride test."</div>
                
                
                <div class="evidence-explanation">CF Foundation consensus guidelines recommend sweat chloride testing for all CFTR-related diagnoses.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Immunoreactive Trypsinogen (IRT)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Elevated in newborn dried blood spots; used as first-tier newborn screening test. Elevated IRT reflects pancreatic injury in utero.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Most cases of CF are identified through newborn screening (NBS)."</div>
                
                
                <div class="evidence-explanation">Newborn screening using IRT is the primary method of CF identification.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Fecal Elastase
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Decreased)</span>
                    
                </div>
                
                <div class="item-desc">Context: Fecal elastase-1 &lt;200 mcg/g indicates pancreatic insufficiency; &lt;100 mcg/g indicates severe insufficiency. Used to confirm exocrine pancreatic function status.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Pancreatic insufficiency is assessed using fecal elastase measurements.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Fat-Soluble Vitamins (A, D, E, K)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Decreased)</span>
                    
                </div>
                
                <div class="item-desc">Context: Deficiencies common due to fat malabsorption in pancreatic-insufficient patients. Levels should be monitored annually.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Malabsorption from pancreatic insufficiency causes fat-soluble vitamin deficiencies.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Liver Enzymes
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Variable)</span>
                    
                </div>
                
                <div class="item-desc">Context: Elevated ALT, AST, and GGT may indicate CF liver disease. GGT is often the first to elevate.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33526571" target="_blank">PMID:33526571</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility."</div>
                
                
                <div class="evidence-explanation">Liver dysfunction in CF is monitored using liver enzyme measurements.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Blood Glucose / HbA1c
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Variable)</span>
                    
                </div>
                
                <div class="item-desc">Context: Annual oral glucose tolerance test recommended from age 10 for CFRD screening. HbA1c is unreliable in CF due to increased red cell turnover.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility."</div>
                
                
                <div class="evidence-explanation">CF-related diabetes requires monitoring of glucose levels.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Sputum Microbiology
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Variable)</span>
                    
                </div>
                
                <div class="item-desc">Context: Routine sputum cultures guide antibiotic therapy. Typical organisms include Staphylococcus aureus, Pseudomonas aeruginosa, Burkholderia cepacia complex, and non-tuberculous mycobacteria.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30986316" target="_blank">PMID:30986316</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cystic fibrosis (CF) is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial airway infection."</div>
                
                
                <div class="evidence-explanation">Chronic endobronchial infection is monitored through sputum microbiology.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        
        <div class="card" id="trials">
            <div class="card-header">
                <div class="card-icon" style="background: #f5f3ff; color: #a855f7;">üî¨</div>
                <h2 class="card-title">Clinical Trials</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT03525444
                    
                    <span class="tag tag-phase">PHASE_III</span>
                    
                    
                    <span class="tag tag-status">COMPLETED</span>
                    
                </div>
                
                <div class="item-desc">Phase 3, randomized, double-blind, placebo-controlled trial evaluating elexacaftor-tezacaftor-ivacaftor in patients aged 12+ with cystic fibrosis heterozygous for F508del and a minimal-function CFTR mutation. This landmark trial led to FDA approval of Trikafta.</div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #6b21a8;">Target Phenotypes:</strong>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Bronchiectasis
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0002110" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                    <span class="tag" style="background: #ede9fe; color: #6b21a8; font-size: 0.8rem;">
                        Recurrent respiratory infections
                        
                        <a href="http://purl.obolibrary.org/obo/HP_0002205" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31697873" target="_blank">PMID:31697873</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Elexacaftor-tezacaftor-ivacaftor was efficacious in patients with cystic fibrosis with Phe508del-minimal function genotypes, in whom previous CFTR modulator regimens were ineffective."</div>
                
                
                <div class="evidence-explanation">This Phase 3 trial established efficacy of Trikafta for CF patients with one F508del allele plus a minimal-function mutation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Cystic Fibrosis
creation_date: &#39;2025-12-19T14:27:56Z&#39;
updated_date: &#39;2026-02-11T19:57:18Z&#39;
description: &gt;-
  Cystic fibrosis is a common life-limiting autosomal recessive genetic disorder
  caused by mutations in the CFTR gene encoding the cystic fibrosis transmembrane
  conductance regulator, a chloride and bicarbonate channel expressed in epithelial
  cells. CFTR dysfunction leads to dehydrated, viscous secretions in multiple organ
  systems, most critically the airways and pancreas. Nearly 2,000 CFTR variants have
  been identified, with the Phe508del (F508del) mutation present in nearly 90% of
  patients. The disease is characterized by progressive bronchiectasis, chronic
  bacterial lung infection, exocrine pancreatic insufficiency, male infertility due
  to congenital bilateral absence of the vas deferens, and elevated sweat chloride.
  Multidisciplinary care and CFTR modulator therapies have extended median survival
  beyond 40 years, with the advent of elexacaftor-tezacaftor-ivacaftor (Trikafta)
  representing a transformational advance for the majority of patients.
category: Genetic
parents:
- Respiratory Disease
- Inborn Error of Metabolism
prevalence:
- population: European descent
  percentage: 1 in 2,500 to 3,500 live births
  evidence:
  - reference: PMID:27140670
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Cystic fibrosis is a common life-limiting autosomal recessive genetic disorder, with highest prevalence in Europe, North America, and Australia.&#34;
    explanation: Lancet seminar confirms highest CF prevalence in populations of European descent.
- population: African American
  percentage: 1 in 15,000 to 20,000 live births
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Cystic fibrosis (CF) is one of the most commonly diagnosed genetic disorders.&#34;
    explanation: Pediatric review confirms CF as a common genetic disorder with variable prevalence across populations.
- population: Asian
  percentage: 1 in 30,000 to 100,000 live births
  evidence:
  - reference: PMID:27140670
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Cystic fibrosis is a common life-limiting autosomal recessive genetic disorder, with highest prevalence in Europe, North America, and Australia.&#34;
    explanation: Lower prevalence in Asian populations is implied by highest prevalence being in European-descent populations.
inheritance:
- name: Autosomal Recessive
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Cystic fibrosis (CF) is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial airway infection.&#34;
    explanation: Clinical review confirms autosomal recessive inheritance pattern.
definitions:
- name: CF Foundation Diagnostic Criteria (2017)
  definition_type: CASE_DEFINITION
  description: &gt;-
    Consensus guidelines from the Cystic Fibrosis Foundation for establishing a
    diagnosis of CF in individuals from newborn to adult, requiring evidence of
    CFTR dysfunction via sweat chloride testing combined with clinical features
    or two disease-causing CFTR mutations.
  scope: Diagnosis of cystic fibrosis in all age groups
  criteria_sets:
  - name: Diagnostic criteria for cystic fibrosis
    description: &gt;-
      CF diagnosis requires clinical features consistent with CF in at least one
      organ system OR positive newborn screen, PLUS evidence of CFTR dysfunction
      demonstrated by elevated sweat chloride (&gt;=60 mmol/L) or identification of
      two CF-causing CFTR mutations.
    core_clinical_characteristics:
    - preferred_term: Elevated sweat chloride
      term:
        id: HP:0410017
        label: Abnormal sweat electrolyte concentration
    - preferred_term: Recurrent respiratory infections
      term:
        id: HP:0002205
        label: Recurrent respiratory infections
    - preferred_term: Exocrine pancreatic insufficiency
      term:
        id: HP:0001738
        label: Exocrine pancreatic insufficiency
    - preferred_term: Male infertility
      term:
        id: HP:0003251
        label: Male infertility
    - preferred_term: Meconium ileus
      term:
        id: HP:0004401
        label: Meconium ileus
  evidence:
  - reference: PMID:28129811
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;It is recommended that diagnoses associated with CFTR mutations in all individuals, from newborn to adult, be established by evaluation of CFTR function with a sweat chloride test.&#34;
    explanation: CF Foundation consensus guidelines establish sweat chloride testing as the cornerstone of CF diagnosis.
- name: Newborn Screening Algorithm
  definition_type: DIAGNOSTIC_CRITERIA
  description: &gt;-
    Most CF cases in the US and many other countries are identified through newborn
    screening (NBS) programs that measure immunoreactive trypsinogen (IRT) in dried
    blood spots, followed by CFTR mutation panel or a second IRT measurement. Positive
    screens require diagnostic confirmation with sweat chloride testing.
  scope: Newborn screening for cystic fibrosis
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Most cases of CF are identified through newborn screening (NBS).&#34;
    explanation: Clinical review confirms newborn screening as the primary route to CF diagnosis.
pathophysiology:
- name: CFTR Dysfunction
  description: &gt;-
    Mutations in the CFTR gene cause defective chloride and bicarbonate channel
    function. CFTR is a unique member of the ABC transporter family located
    predominantly in the apical membrane of epithelia where it mediates
    transepithelial salt and liquid movement. Loss of CFTR function leads to
    impaired chloride and bicarbonate secretion across epithelial surfaces
    in the airways, pancreas, intestine, hepatobiliary system, sweat glands,
    and reproductive tract, resulting in dehydrated, acidic secretions.
  cell_types:
  - preferred_term: Epithelial cell
    term:
      id: CL:0000066
      label: epithelial cell
  biological_processes:
  - preferred_term: Chloride Transport
    term:
      id: GO:0006821
      label: chloride transport
  - preferred_term: Ion Transport
    term:
      id: GO:0006811
      label: monoatomic ion transport
  evidence:
  - reference: PMID:9922375
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The cystic fibrosis transmembrane conductance regulator (CFTR) is a unique member of the ABC transporter family that forms a novel Cl- channel. It is located predominantly in the apical membrane of epithelia where it mediates transepithelial salt and liquid movement. Dysfunction of CFTR causes the genetic disease cystic fibrosis.&#34;
    explanation: Comprehensive review establishes CFTR as chloride channel whose dysfunction causes cystic fibrosis.
  - reference: PMID:9922375
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The CFTR is composed of five domains: two membrane-spanning domains (MSDs), two nucleotide-binding domains (NBDs), and a regulatory (R) domain.&#34;
    explanation: Describes the five-domain architecture of CFTR critical to understanding mutation effects.
  downstream:
  - target: Airway Surface Liquid Depletion
    description: Reduced chloride and bicarbonate secretion dehydrates the periciliary layer and airway surface liquid.
  - target: Pancreatic Duct Obstruction
    description: Viscid secretions obstruct pancreatic ducts and promote exocrine destruction.
  - target: Intestinal Obstruction
    description: Dehydrated intestinal secretions cause meconium ileus and distal intestinal obstruction syndrome.
  - target: Sweat Gland Dysfunction
    description: Defective chloride reabsorption in sweat ducts causes elevated sweat chloride concentration.
  - target: Vas Deferens Agenesis
    description: CFTR-dependent defects in Wolffian duct development cause congenital bilateral absence of the vas deferens.
  - target: Hepatobiliary Obstruction
    description: Viscid bile obstructs intrahepatic bile ducts causing focal biliary cirrhosis.
- name: Airway Surface Liquid Depletion
  description: &gt;-
    Loss of CFTR-mediated chloride and bicarbonate secretion on airway epithelial
    surfaces depletes the periciliary liquid layer and airway surface liquid (ASL).
    Concurrent sodium hyperabsorption via ENaC further dehydrates the airway surface.
    The depleted ASL impairs mucociliary clearance by collapsing cilia and tethering
    mucus to the epithelial surface, initiating the cycle of mucus obstruction and infection.
  cell_types:
  - preferred_term: Bronchial epithelial cell
    term:
      id: CL:0002328
      label: bronchial epithelial cell
  biological_processes:
  - preferred_term: Mucus Secretion
    term:
      id: GO:0070254
      label: mucus secretion
  locations:
  - preferred_term: Lung
    term:
      id: UBERON:0002048
      label: lung
  evidence:
  - reference: PMID:23878362
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;CF lungs are characterized by viscous, dehydrated mucus, persistent neutrophilia and chronic infections. ENaC is negatively regulated by CFTR and, in patients with CF, the absence of CFTR results in a double hit of reduced Cl-/HCO3- and H2O secretion as well as ENaC hyperactivity and increased Na+ and H2O absorption.&#34;
    explanation: Review describes ENaC hyperactivity and dehydration mechanism in CF airways.
  downstream:
  - target: Mucus Plugging and Airway Obstruction
    description: Dehydrated ASL collapses cilia and creates hyperviscous adherent mucus plaques.
- name: Mucus Plugging and Airway Obstruction
  description: &gt;-
    Defective CFTR leads to depleted airway surface liquid and thick mucus.
    Impaired mucociliary clearance creates mucus plugs in small and medium airways,
    causing airflow obstruction and air trapping. The stagnant mucus forms an
    anaerobic niche that favors bacterial colonization and biofilm formation.
  cell_types:
  - preferred_term: Bronchial epithelial cell
    term:
      id: CL:0002328
      label: bronchial epithelial cell
  biological_processes:
  - preferred_term: Mucus Secretion
    term:
      id: GO:0070254
      label: mucus secretion
  evidence:
  - reference: PMID:22711878
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &#34;Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype.&#34;
    explanation: Study demonstrates the mechanistic link between CFTR dysfunction and abnormal mucus properties.
  downstream:
  - target: Chronic Bacterial Infection
    description: Stagnant mucus permits persistent bacterial colonization and biofilm formation.
  - target: Bronchiectasis and Airway Remodeling
    description: Chronic obstruction and infection cause structural airway damage.
- name: Chronic Bacterial Infection
  description: &gt;-
    The CF airway is chronically colonized by characteristic pathogens.
    Staphylococcus aureus typically predominates in early childhood, followed by
    Pseudomonas aeruginosa which becomes the dominant pathogen in adolescence and
    adulthood. P. aeruginosa transitions to a mucoid phenotype with alginate
    biofilm production, making eradication extremely difficult. Other important
    pathogens include Burkholderia cepacia complex, Stenotrophomonas maltophilia,
    Achromobacter xylosoxidans, and non-tuberculous mycobacteria.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Cystic fibrosis (CF) is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial airway infection.&#34;
    explanation: Clinical review identifies chronic endobronchial infection as a defining characteristic of CF.
  biological_processes:
  - preferred_term: Defense response to bacterium
    term:
      id: GO:0042742
      label: defense response to bacterium
  downstream:
  - target: Neutrophilic Airway Inflammation
    description: Bacterial infection triggers massive neutrophil recruitment to the airways.
  - target: Bronchiectasis and Airway Remodeling
    description: Chronic infection drives progressive structural airway damage.
- name: Neutrophilic Airway Inflammation
  description: &gt;-
    The CF airway is characterized by an exaggerated and sustained neutrophilic
    inflammatory response. Massive neutrophil influx releases proteases (especially
    neutrophil elastase), oxidants, and extracellular DNA that further damage the
    airway epithelium, impair mucociliary clearance, and perpetuate the vicious
    cycle of infection and inflammation. Neutrophil elastase overwhelms
    antiprotease defenses and directly damages airway tissue. The resulting
    free DNA from necrotic neutrophils further increases mucus viscosity.
  cell_types:
  - preferred_term: Neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:29258516
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The role of neutrophil elastase (NE) is poorly understood in bronchiectasis because of the lack of preclinical data and so most of the assumptions made about NE inhibitor potential benefit is based on data from CF.&#34;
    explanation: Review confirms neutrophil elastase as a key marker of inflammation in CF and bronchiectasis.
  downstream:
  - target: Bronchiectasis and Airway Remodeling
    description: Proteolytic damage from neutrophil elastase destroys airway walls.
- name: Bronchiectasis and Airway Remodeling
  description: &gt;-
    The vicious cycle of mucus obstruction, chronic infection, and neutrophilic
    inflammation causes progressive, irreversible bronchiectasis. Airway walls
    become thickened, dilated, and scarred. Ongoing proteolytic damage from
    neutrophil elastase and matrix metalloproteinases destroys cartilage and
    elastic tissue. Progressive bronchiectasis leads to respiratory failure,
    which is the leading cause of death in CF.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;This latter feature results in progressive bronchiectasis and ultimately respiratory failure, which is the leading cause of death in patients with CF.&#34;
    explanation: Clinical review confirms progressive bronchiectasis leading to respiratory failure as the primary cause of mortality.
  locations:
  - preferred_term: Lung
    term:
      id: UBERON:0002048
      label: lung
  downstream:
  - target: Respiratory Failure
    description: End-stage bronchiectasis leads to hypoxemic and hypercapnic respiratory failure.
- name: Respiratory Failure
  description: &gt;-
    End-stage CF lung disease results in progressive respiratory failure with
    hypoxemia, hypercapnia, and cor pulmonale. Respiratory failure is the leading
    cause of death in CF patients and the primary indication for lung
    transplantation.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;This latter feature results in progressive bronchiectasis and ultimately respiratory failure, which is the leading cause of death in patients with CF.&#34;
    explanation: Respiratory failure is confirmed as the leading cause of CF mortality.
- name: Pancreatic Duct Obstruction
  description: &gt;-
    CFTR dysfunction in pancreatic ductal epithelium impairs bicarbonate and fluid
    secretion, leading to viscid secretions that obstruct pancreatic ducts. The
    resulting ductal obstruction causes premature activation of digestive enzymes,
    autodigestion, acinar cell destruction, and progressive fibrosis. In utero
    pancreatic damage begins in the second trimester in severely affected individuals,
    and pancreatic insufficiency is present at birth in most patients with two
    severe CFTR mutations.
  cell_types:
  - preferred_term: Pancreatic ductal cell
    term:
      id: CL:0002079
      label: pancreatic ductal cell
  - preferred_term: Pancreatic acinar cell
    term:
      id: CL:0002064
      label: pancreatic acinar cell
  locations:
  - preferred_term: Pancreas
    term:
      id: UBERON:0001264
      label: pancreas
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Pediatric review confirms pancreatic insufficiency and dysfunction as core CF manifestations.
  downstream:
  - target: Exocrine Pancreatic Insufficiency
    description: Acinar destruction reduces digestive enzyme delivery to the intestine.
  - target: CF-Related Diabetes
    description: Progressive fibrosis and islet destruction impair insulin secretion.
- name: Exocrine Pancreatic Insufficiency
  description: &gt;-
    Destruction of exocrine pancreatic tissue causes insufficient production of
    digestive enzymes including lipase, amylase, and proteases. Present in 85-90%
    of CF patients, pancreatic insufficiency causes fat and protein malabsorption
    leading to steatorrhea, failure to thrive, and fat-soluble vitamin deficiency
    (vitamins A, D, E, K). Pancreatic sufficiency is more common in patients with
    at least one mild (class IV-V) CFTR mutation.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Cystic fibrosis (CF) is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial airway infection.&#34;
    explanation: Clinical review identifies pancreatic insufficiency as a defining characteristic of cystic fibrosis.
  downstream:
  - target: Fat Malabsorption
    description: Low pancreatic lipase causes fat malabsorption with steatorrhea.
  - target: Fat-Soluble Vitamin Deficiency
    description: Malabsorption of vitamins A, D, E, K causes deficiency states.
  - target: Protein-Calorie Malnutrition
    description: Impaired digestion and absorption lead to failure to thrive.
- name: Fat Malabsorption
  description: &gt;-
    Insufficient pancreatic lipase causes malabsorption of dietary fat, resulting in
    steatorrhea (fatty, bulky, foul-smelling stools), caloric loss, and deficiency
    of fat-soluble vitamins. Fat malabsorption is a major contributor to
    malnutrition and failure to thrive in CF.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Pediatric review confirms malabsorption as a clinical characteristic of CF.
  downstream:
  - target: Fat-Soluble Vitamin Deficiency
- name: Fat-Soluble Vitamin Deficiency
  description: &gt;-
    Malabsorption of fat-soluble vitamins A, D, E, and K leads to specific
    deficiency states. Vitamin A deficiency can cause night blindness, vitamin D
    deficiency contributes to CF bone disease, vitamin E deficiency may cause
    neurological symptoms, and vitamin K deficiency increases bleeding risk.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Malabsorption leads to vitamin deficiencies as part of the CF nutritional phenotype.
- name: Protein-Calorie Malnutrition
  description: &gt;-
    Combined effects of pancreatic insufficiency, increased metabolic demands from
    chronic infection and inflammation, and poor appetite lead to protein-calorie
    malnutrition, failure to thrive in children, and poor weight maintenance in
    adults. Nutritional status is strongly correlated with lung function and survival.
  evidence:
  - reference: PMID:33178516
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;It classically presents in childhood with chronic productive cough, malabsorption causing steatorrhea, and failure to thrive.&#34;
    explanation: Case report review confirms malabsorption and failure to thrive as classic CF presentations.
- name: CF-Related Diabetes
  description: &gt;-
    Progressive fibrosis and fatty infiltration of the pancreas destroys
    islets of Langerhans, reducing insulin secretion capacity. CF-related diabetes
    (CFRD) is distinct from type 1 and type 2 diabetes, characterized primarily by
    insulin insufficiency with variable insulin resistance, especially during
    pulmonary exacerbations. CFRD affects up to 50% of adult CF patients and is
    associated with accelerated decline in lung function and increased mortality
    if untreated.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility.&#34;
    explanation: Clinical review lists diabetes mellitus among established complications of CF.
  cell_types:
  - preferred_term: Pancreatic beta cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  locations:
  - preferred_term: Pancreas
    term:
      id: UBERON:0001264
      label: pancreas
- name: Intestinal Obstruction
  description: &gt;-
    Dehydrated intestinal secretions cause bowel obstruction at different ages.
    Meconium ileus occurs in 15-20% of CF neonates due to inspissated meconium
    in the distal ileum. In older children and adults, distal intestinal
    obstruction syndrome (DIOS) presents with similar pathophysiology in the
    ileocecal region. Constipation is also common due to dehydrated intestinal
    contents.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility.&#34;
    explanation: Clinical review lists bowel obstruction among established complications of CF.
- name: Hepatobiliary Obstruction
  description: &gt;-
    CFTR dysfunction in cholangiocytes causes viscid bile secretions that obstruct
    intrahepatic bile ductules. This leads to focal biliary cirrhosis, which can
    progress to multilobular cirrhosis with portal hypertension in 5-10% of CF
    patients. CF liver disease is the third leading cause of death after
    respiratory failure and transplant complications.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility.&#34;
    explanation: Clinical review lists hepatobiliary disease among established complications of CF.
  cell_types:
  - preferred_term: Cholangiocyte
    term:
      id: CL:1000488
      label: cholangiocyte
  locations:
  - preferred_term: Liver
    term:
      id: UBERON:0002107
      label: liver
- name: Sweat Gland Dysfunction
  description: &gt;-
    In sweat glands, CFTR is required for chloride reabsorption in the sweat duct.
    Loss of CFTR function results in failure to reabsorb chloride from primary sweat,
    producing sweat with elevated chloride concentration. This is the basis of the
    diagnostic sweat chloride test. Excessive salt loss can cause hyponatremic
    dehydration, especially in hot weather or during exercise.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Diagnosis of CF is confirmed by demonstration of elevated sweat chloride.&#34;
    explanation: Elevated sweat chloride reflects defective CFTR-mediated chloride reabsorption in sweat ducts.
- name: Vas Deferens Agenesis
  description: &gt;-
    CFTR is required for normal development of the Wolffian duct derivatives.
    Congenital bilateral absence of the vas deferens (CBAVD) occurs in approximately
    97-98% of males with CF due to inspissation and atresia of the vas deferens
    during fetal development. CBAVD causes obstructive azoospermia and male
    infertility. Notably, CBAVD can occur as an isolated finding in males who
    carry one or two CFTR mutations with residual function, representing a
    CFTR-related disorder.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility.&#34;
    explanation: Clinical review confirms infertility as an established complication of CF.
- name: Sinonasal Disease
  description: &gt;-
    CFTR dysfunction in the sinonasal epithelium causes mucus retention and chronic
    inflammation in the paranasal sinuses. Chronic rhinosinusitis affects nearly all
    CF patients. Nasal polyposis occurs in 10-32% of CF patients and is unusual in
    children without CF, making it an important diagnostic clue.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility.&#34;
    explanation: Clinical review lists sinusitis among established complications of CF.
- name: CF Bone Disease
  description: &gt;-
    CF-related bone disease results from multiple converging mechanisms including
    vitamin D deficiency from fat malabsorption, chronic systemic inflammation
    with elevated cytokines (IL-6, TNF-alpha) that promote osteoclast activity,
    reduced physical activity, delayed puberty with reduced sex steroids,
    glucocorticoid use, and possibly direct CFTR effects on osteoblast function.
    Osteopenia and osteoporosis are common in adults with CF.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Malnutrition from pancreatic insufficiency contributes to bone disease in CF patients.
phenotypes:
# Respiratory phenotypes
- category: Respiratory
  name: Chronic Productive Cough
  description: Persistent cough with purulent sputum production, often the earliest respiratory symptom of CF.
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: One of the classic presenting symptoms of CF along with steatorrhea and failure to thrive.
  phenotype_term:
    preferred_term: Chronic Productive Cough
    term:
      id: HP:0031245
      label: Productive cough
  evidence:
  - reference: PMID:33178516
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;It classically presents in childhood with chronic productive cough, malabsorption causing steatorrhea, and failure to thrive.&#34;
    explanation: Review confirms chronic productive cough as a classic presentation of cystic fibrosis.
- category: Respiratory
  name: Recurrent Respiratory Infections
  description: Chronic and recurrent lower respiratory tract infections with characteristic CF pathogens including Pseudomonas aeruginosa and Staphylococcus aureus.
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Chronic Pseudomonas aeruginosa and Staphylococcus aureus infections are hallmarks of CF lung disease.
  phenotype_term:
    preferred_term: Recurrent Respiratory Infections
    term:
      id: HP:0002205
      label: Recurrent respiratory infections
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Cystic fibrosis (CF) is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial airway infection.&#34;
    explanation: Clinical review identifies chronic airway infection as a defining characteristic of cystic fibrosis.
- category: Respiratory
  name: Bronchiectasis
  description: Progressive airway damage from chronic infection and inflammation leading to permanent bronchial dilation.
  frequency: VERY_FREQUENT
  notes: Progressive and eventually universal in CF patients; the primary driver of morbidity and mortality.
  phenotype_term:
    preferred_term: Bronchiectasis
    term:
      id: HP:0002110
      label: Bronchiectasis
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;This latter feature results in progressive bronchiectasis and ultimately respiratory failure, which is the leading cause of death in patients with CF.&#34;
    explanation: Clinical review confirms progressive bronchiectasis as a consequence of chronic airway infection in CF.
- category: Respiratory
  name: Hemoptysis
  description: Coughing up blood due to erosion of bronchial arteries by chronic inflammation and bronchiectasis. Massive hemoptysis (&gt;240 mL/day) is a life-threatening complication requiring bronchial artery embolization.
  frequency: FREQUENT
  notes: Minor hemoptysis is common; massive hemoptysis occurs in 4-5% of patients.
  phenotype_term:
    preferred_term: Hemoptysis
    term:
      id: HP:0002105
      label: Hemoptysis
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Progressive obstructive lung disease leads to complications including hemoptysis.
- category: Respiratory
  name: Pneumothorax
  description: Spontaneous pneumothorax from rupture of subpleural blebs, occurring in patients with advanced lung disease. Risk increases with severity of airflow obstruction.
  frequency: OCCASIONAL
  notes: Occurs in 3-4% of CF patients; recurrence rate is high.
  phenotype_term:
    preferred_term: Pneumothorax
    term:
      id: HP:0002107
      label: Pneumothorax
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Progressive obstructive lung disease is associated with complications such as pneumothorax.
- category: Respiratory
  name: Allergic Bronchopulmonary Aspergillosis
  description: Hypersensitivity response to Aspergillus fumigatus colonization of CF airways, causing worsening airflow obstruction, mucus plugging, and central bronchiectasis.
  frequency: OCCASIONAL
  notes: Affects 2-15% of CF patients; requires high index of suspicion.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Progressive obstructive lung disease encompasses various complications including fungal sensitization.
- category: Respiratory
  name: Digital Clubbing
  description: Enlargement and rounding of the fingertips and nail beds due to chronic hypoxemia from progressive lung disease.
  frequency: FREQUENT
  notes: Develops with progression of lung disease; correlates with severity.
  phenotype_term:
    preferred_term: Digital Clubbing
    term:
      id: HP:0001217
      label: Clubbing
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Progressive obstructive lung disease leads to chronic hypoxemia and clubbing.
# ENT phenotypes
- category: ENT
  name: Nasal Polyposis
  description: Benign mucosal growths in the nasal passages and paranasal sinuses. Nasal polyposis in children is highly suggestive of CF and should prompt diagnostic evaluation.
  frequency: FREQUENT
  notes: Present in 10-32% of CF patients. In children, nasal polyps are uncommon outside of CF and should trigger sweat testing.
  phenotype_term:
    preferred_term: Nasal Polyposis
    term:
      id: HP:0100582
      label: Nasal polyposis
- category: ENT
  name: Chronic Sinusitis
  description: Near-universal chronic rhinosinusitis in CF patients due to mucus retention and inflammation in the paranasal sinuses. Often causes nasal obstruction, facial pain, and anosmia.
  frequency: VERY_FREQUENT
  notes: Radiographic sinusitis is nearly universal; symptomatic disease varies.
  phenotype_term:
    preferred_term: Chronic Sinusitis
    term:
      id: HP:0011109
      label: Chronic sinusitis
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility.&#34;
    explanation: Clinical review lists sinusitis among established complications of CF.
# Gastrointestinal phenotypes
- category: Gastrointestinal
  name: Exocrine Pancreatic Insufficiency
  description: Insufficient production of pancreatic digestive enzymes causing malabsorption of fats, proteins, and fat-soluble vitamins.
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Present in 85-90% of CF patients, typically those with two severe CFTR mutations. Patients with at least one mild mutation may retain pancreatic sufficiency.
  phenotype_term:
    preferred_term: Pancreatic Insufficiency
    term:
      id: HP:0001738
      label: Exocrine pancreatic insufficiency
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Cystic fibrosis (CF) is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial airway infection.&#34;
    explanation: Clinical review identifies pancreatic insufficiency as a defining characteristic of cystic fibrosis.
- category: Gastrointestinal
  name: Steatorrhea
  description: Fatty, bulky, foul-smelling stools resulting from fat malabsorption due to pancreatic lipase deficiency.
  frequency: VERY_FREQUENT
  notes: A classic presenting symptom of CF in infancy and early childhood.
  phenotype_term:
    preferred_term: Steatorrhea
    term:
      id: HP:0002570
      label: Steatorrhea
  evidence:
  - reference: PMID:33178516
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;It classically presents in childhood with chronic productive cough, malabsorption causing steatorrhea, and failure to thrive.&#34;
    explanation: Review confirms steatorrhea as a classic presentation of cystic fibrosis due to malabsorption.
- category: Gastrointestinal
  name: Meconium Ileus
  description: Neonatal bowel obstruction caused by inspissated meconium in the distal ileum, often the first clinical manifestation of CF.
  frequency: OCCASIONAL
  diagnostic: true
  notes: Present in 15-20% of CF newborns. May be complicated by volvulus, atresia, or perforation. Meconium ileus in a neonate is highly suggestive of CF.
  phenotype_term:
    preferred_term: Meconium Ileus
    term:
      id: HP:0004401
      label: Meconium ileus
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility.&#34;
    explanation: Clinical review lists bowel obstruction (including meconium ileus) among established complications of CF.
- category: Gastrointestinal
  name: Distal Intestinal Obstruction Syndrome
  description: Partial or complete intestinal obstruction in the ileocecal region due to accumulation of viscid intestinal contents. Analogous to meconium ileus but occurring in older children and adults.
  frequency: OCCASIONAL
  notes: Occurs in approximately 10-15% of CF patients. Risk factors include pancreatic insufficiency, dehydration, and inadequate enzyme replacement.
  phenotype_term:
    preferred_term: Intestinal Obstruction
    term:
      id: HP:0005214
      label: Intestinal obstruction
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility.&#34;
    explanation: Bowel obstruction including DIOS is an established complication in CF patients.
- category: Gastrointestinal
  name: Rectal Prolapse
  description: Protrusion of rectal mucosa through the anus, historically a common presenting feature of CF in undiagnosed children due to malnutrition and chronic cough-related straining.
  frequency: OCCASIONAL
  notes: Less common since advent of newborn screening and early treatment.
  phenotype_term:
    preferred_term: Rectal Prolapse
    term:
      id: HP:0002035
      label: Rectal prolapse
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Malnutrition from pancreatic insufficiency contributes to complications like rectal prolapse.
- category: Gastrointestinal
  name: Gastroesophageal Reflux
  description: Increased gastroesophageal reflux in CF patients, potentially exacerbated by cough, chest physiotherapy, and increased abdominal pressure. May worsen lung disease through aspiration.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Gastroesophageal Reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: GI complications are common in CF and include gastroesophageal reflux.
# Hepatobiliary phenotypes
- category: Hepatobiliary
  name: Focal Biliary Cirrhosis
  description: Obstruction of intrahepatic bile ductules by viscid secretions causes focal biliary fibrosis, which may progress to multilobular cirrhosis with portal hypertension in 5-10% of patients.
  frequency: OCCASIONAL
  notes: CF liver disease is the third leading cause of CF mortality. Ursodeoxycholic acid may slow progression.
  phenotype_term:
    preferred_term: Biliary Cirrhosis
    term:
      id: HP:0002613
      label: Biliary cirrhosis
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility.&#34;
    explanation: Clinical review lists hepatobiliary disease among established complications of CF.
- category: Hepatobiliary
  name: Portal Hypertension
  description: Increased portal venous pressure from multilobular biliary cirrhosis, which may cause variceal bleeding, splenomegaly, and ascites.
  frequency: OCCASIONAL
  notes: Occurs in patients who progress to multilobular cirrhosis. May require portosystemic shunting or liver transplantation.
  phenotype_term:
    preferred_term: Portal Hypertension
    term:
      id: HP:0001409
      label: Portal hypertension
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Liver and pancreatic dysfunction in CF includes cirrhosis leading to portal hypertension.
# Endocrine phenotypes
- category: Endocrine
  name: CF-Related Diabetes
  description: Diabetes caused by progressive destruction of pancreatic islets, characterized by insulin insufficiency with variable insulin resistance. Distinct from type 1 and type 2 diabetes. Associated with accelerated decline in lung function and increased mortality if untreated.
  frequency: FREQUENT
  notes: Prevalence increases with age, affecting up to 20% of adolescents and 50% of adults with CF. Annual screening with oral glucose tolerance test recommended from age 10.
  phenotype_term:
    preferred_term: Diabetes Mellitus
    term:
      id: HP:0000819
      label: Diabetes mellitus
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility.&#34;
    explanation: Clinical review lists diabetes mellitus among established complications of CF.
- category: Endocrine
  name: Delayed Puberty
  description: Delayed onset of puberty due to chronic illness, malnutrition, and possibly direct effects of CFTR dysfunction on gonadal function.
  frequency: FREQUENT
  notes: More common when nutritional status is poor.
  phenotype_term:
    preferred_term: Delayed Puberty
    term:
      id: HP:0000823
      label: Delayed puberty
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Malnutrition from pancreatic insufficiency contributes to delayed puberty in CF patients.
# Growth phenotypes
- category: Growth
  name: Failure to Thrive
  description: Poor weight gain and growth failure due to pancreatic insufficiency, malabsorption, increased caloric requirements from chronic lung infection, and poor appetite.
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: A classic presenting feature, especially before newborn screening era. Nutritional status strongly correlates with lung function and survival.
  phenotype_term:
    preferred_term: Failure to Thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:33178516
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;It classically presents in childhood with chronic productive cough, malabsorption causing steatorrhea, and failure to thrive.&#34;
    explanation: Review confirms failure to thrive as a classic presentation of cystic fibrosis.
- category: Growth
  name: Short Stature
  description: Reduced height for age resulting from chronic malnutrition, systemic inflammation, and delayed puberty.
  frequency: FREQUENT
  notes: Improved with optimized nutritional support and CFTR modulator therapy.
  phenotype_term:
    preferred_term: Short Stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Malnutrition from pancreatic insufficiency contributes to growth failure and short stature.
# Reproductive phenotypes
- category: Reproductive
  name: Male Infertility
  description: Obstructive azoospermia due to congenital bilateral absence of the vas deferens (CBAVD) in 97-98% of males with CF. Spermatogenesis is usually normal, and assisted reproduction is possible via sperm extraction techniques.
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: CBAVD can also occur as an isolated finding in males carrying one or two CFTR mutations, representing a CFTR-related disorder.
  phenotype_term:
    preferred_term: Male Infertility
    term:
      id: HP:0003251
      label: Male infertility
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility.&#34;
    explanation: Clinical review lists infertility among the established complications of cystic fibrosis.
- category: Reproductive
  name: Reduced Female Fertility
  description: Reduced fertility in females with CF due to thick cervical mucus that impairs sperm transport. Fertility is improved with CFTR modulator therapy and nutritional optimization.
  frequency: FREQUENT
  notes: Not absolute infertility; many CF women conceive, especially with improved health status on modulator therapy.
  phenotype_term:
    preferred_term: Reduced Female Fertility
    term:
      id: HP:0008222
      label: Female infertility
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Reproductive complications including reduced fertility affect CF patients.
# Metabolic phenotypes
- category: Metabolic
  name: Hyponatremic Dehydration
  description: Excessive sodium and chloride loss in sweat predisposes CF patients to salt-depletion dehydration, especially in hot weather, during exercise, or with gastroenteritis.
  frequency: OCCASIONAL
  notes: Can be a presenting feature in infancy. Salt supplementation is recommended.
  phenotype_term:
    preferred_term: Hyponatremia
    term:
      id: HP:0002902
      label: Hyponatremia
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility.&#34;
    explanation: Clinical review lists hyponatremic dehydration among established complications of CF.
- category: Metabolic
  name: Fat-Soluble Vitamin Deficiency
  description: Deficiency of vitamins A, D, E, and K due to fat malabsorption from pancreatic insufficiency. Vitamin D deficiency contributes to bone disease; vitamin K deficiency increases bleeding risk.
  frequency: VERY_FREQUENT
  notes: Routine supplementation of fat-soluble vitamins is standard of care.
  phenotype_term:
    preferred_term: Intestinal malabsorption
    term:
      id: HP:0002024
      label: Malabsorption
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Malabsorption from pancreatic insufficiency causes vitamin deficiencies.
# Musculoskeletal phenotypes
- category: Musculoskeletal
  name: Osteoporosis
  description: Reduced bone mineral density resulting from vitamin D deficiency, chronic inflammation, reduced physical activity, delayed puberty, and glucocorticoid exposure. Fracture risk is increased, particularly vertebral and rib fractures.
  frequency: FREQUENT
  notes: Bone density screening with DXA recommended for adults with CF.
  phenotype_term:
    preferred_term: Osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Malnutrition and vitamin D deficiency from malabsorption contribute to osteoporosis.
biochemical:
- name: Sweat Chloride
  presence: Elevated
  context: Sweat chloride &gt;=60 mmol/L is diagnostic of CF; 30-59 mmol/L is intermediate and requires further evaluation; &lt;30 mmol/L makes CF unlikely.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Diagnosis of CF is confirmed by demonstration of elevated sweat chloride.&#34;
    explanation: Elevated sweat chloride is the diagnostic hallmark of CF.
  - reference: PMID:28129811
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;It is recommended that diagnoses associated with CFTR mutations in all individuals, from newborn to adult, be established by evaluation of CFTR function with a sweat chloride test.&#34;
    explanation: CF Foundation consensus guidelines recommend sweat chloride testing for all CFTR-related diagnoses.
- name: Immunoreactive Trypsinogen (IRT)
  presence: Elevated
  context: Elevated in newborn dried blood spots; used as first-tier newborn screening test. Elevated IRT reflects pancreatic injury in utero.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Most cases of CF are identified through newborn screening (NBS).&#34;
    explanation: Newborn screening using IRT is the primary method of CF identification.
- name: Fecal Elastase
  presence: Decreased
  context: Fecal elastase-1 &lt;200 mcg/g indicates pancreatic insufficiency; &lt;100 mcg/g indicates severe insufficiency. Used to confirm exocrine pancreatic function status.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Pancreatic insufficiency is assessed using fecal elastase measurements.
- name: Fat-Soluble Vitamins (A, D, E, K)
  presence: Decreased
  context: Deficiencies common due to fat malabsorption in pancreatic-insufficient patients. Levels should be monitored annually.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Malabsorption from pancreatic insufficiency causes fat-soluble vitamin deficiencies.
- name: Liver Enzymes
  presence: Variable
  context: Elevated ALT, AST, and GGT may indicate CF liver disease. GGT is often the first to elevate.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Liver dysfunction in CF is monitored using liver enzyme measurements.
- name: Blood Glucose / HbA1c
  presence: Variable
  context: Annual oral glucose tolerance test recommended from age 10 for CFRD screening. HbA1c is unreliable in CF due to increased red cell turnover.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility.&#34;
    explanation: CF-related diabetes requires monitoring of glucose levels.
- name: Sputum Microbiology
  presence: Variable
  context: Routine sputum cultures guide antibiotic therapy. Typical organisms include Staphylococcus aureus, Pseudomonas aeruginosa, Burkholderia cepacia complex, and non-tuberculous mycobacteria.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Cystic fibrosis (CF) is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial airway infection.&#34;
    explanation: Chronic endobronchial infection is monitored through sputum microbiology.
genetic:
- name: CFTR
  association: Causative
  notes: &gt;-
    The CFTR gene (7q31.2) encodes the cystic fibrosis transmembrane conductance
    regulator, a 1480-amino acid chloride and bicarbonate channel. Nearly 2,000
    CFTR variants have been identified. The Clinical and Functional Translation of
    CFTR (CFTR2) project has systematically characterized disease liability of the
    most common variants, with 159 variants at allele frequency &gt;=0.01%, of which
    127 met both clinical and functional criteria for disease causation.
  evidence:
  - reference: PMID:31697873
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, and nearly 90% of patients have at least one copy of the Phe508del CFTR mutation.&#34;
    explanation: Phase 3 trial confirms CFTR mutations cause CF and F508del is the most common mutation.
  - reference: PMID:23974870
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Few of the almost 2,000 variants in the cystic fibrosis transmembrane conductance regulator gene CFTR have empirical evidence that they cause cystic fibrosis.&#34;
    explanation: CFTR2 project establishes the scope of CFTR variant heterogeneity.
  - reference: PMID:23974870
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;we collected both genotype and phenotype data for 39,696 individuals with cystic fibrosis in registries and clinics in North America and Europe&#34;
    explanation: CFTR2 project provides the largest systematic analysis of CFTR variant-disease relationships.
  variants:
  - name: F508del (Phe508del)
    description: &gt;-
      Deletion of phenylalanine at position 508 in the CFTR protein. The most common
      CF-causing mutation, present on at least one allele in nearly 90% of CF
      patients. Causes misfolding of CFTR protein leading to endoplasmic reticulum
      retention, proteasomal degradation, and near-complete absence of CFTR at the
      cell surface (Class II defect). The small amount of protein reaching the
      surface also has reduced channel open probability (Class III) and reduced
      stability (Class VI).
    evidence:
    - reference: PMID:31697873
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#34;nearly 90% of patients have at least one copy of the Phe508del CFTR mutation&#34;
      explanation: Confirms F508del is present in nearly 90% of CF patients.
  - name: G551D (Gly551Asp)
    description: &gt;-
      Missense mutation causing glycine-to-aspartate substitution at position 551.
      CFTR protein reaches the cell surface normally but has severely reduced channel
      gating (Class III defect). The first CFTR mutation for which targeted modulator
      therapy (ivacaftor) was approved, producing dramatic clinical benefit.
    evidence:
    - reference: PMID:22047557
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#34;The change from baseline through week 24 in the percent of predicted FEV(1) was greater by 10.6 percentage points in the ivacaftor group than in the placebo group (P&lt;0.001).&#34;
      explanation: Landmark Phase 3 trial demonstrating ivacaftor efficacy in G551D patients.
  - name: G542X
    description: &gt;-
      Nonsense mutation creating a premature stop codon at position 542. No functional
      CFTR protein is produced (Class I defect). One of the most common severe
      mutations after F508del.
    evidence:
    - reference: PMID:23974870
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#34;These variants were evaluated for both clinical severity and functional consequence, with 127 (80%) meeting both clinical and functional criteria consistent with disease.&#34;
      explanation: CFTR2 project establishes disease liability of common CFTR variants including nonsense mutations.
  - name: W1282X
    description: &gt;-
      Nonsense mutation at position 1282 causing premature termination. Class I defect
      with no functional protein produced. Common in Ashkenazi Jewish populations.
    evidence:
    - reference: PMID:23974870
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#34;These variants were evaluated for both clinical severity and functional consequence, with 127 (80%) meeting both clinical and functional criteria consistent with disease.&#34;
      explanation: CFTR2 project classifies W1282X as a disease-causing variant.
  - name: N1303K
    description: &gt;-
      Missense mutation causing protein misfolding and degradation similar to F508del
      (Class II defect).
    evidence:
    - reference: PMID:23974870
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#34;These variants were evaluated for both clinical severity and functional consequence, with 127 (80%) meeting both clinical and functional criteria consistent with disease.&#34;
      explanation: CFTR2 project evaluates N1303K as a disease-causing variant.
  - name: R117H
    description: &gt;-
      Missense mutation producing CFTR with reduced chloride conductance (Class IV
      defect). Associated with variable phenotype depending on the polythymidine
      tract variant (5T, 7T, 9T) on the same allele. R117H-5T causes more severe
      disease; R117H-7T may cause CFTR-related disorder or be benign.
diagnosis:
- name: Sweat Chloride Test (Quantitative Pilocarpine Iontophoresis)
  description: &gt;-
    Gold standard diagnostic test for CF. Pilocarpine iontophoresis stimulates
    localized sweating; sweat is collected and chloride concentration measured.
    Chloride &gt;=60 mmol/L is diagnostic, 30-59 mmol/L is intermediate, &lt;30 mmol/L
    is CF-unlikely.
  notes: Must be performed at a CF Foundation-accredited laboratory. Minimum sweat volume required for reliable results. Should be performed on two separate occasions.
  evidence:
  - reference: PMID:28129811
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;It is recommended that diagnoses associated with CFTR mutations in all individuals, from newborn to adult, be established by evaluation of CFTR function with a sweat chloride test.&#34;
    explanation: CF Foundation consensus guidelines establish sweat chloride as the recommended diagnostic test.
- name: CFTR Genetic Testing
  description: &gt;-
    Identification of two disease-causing CFTR mutations confirms the diagnosis.
    Panel testing covers the most common mutations; expanded sequencing and
    deletion/duplication analysis can identify rare variants. The CFTR2 database
    provides clinical classification of variants.
  notes: Genetic testing alone is insufficient for diagnosis if sweat chloride is normal, as some variants have variable penetrance.
  evidence:
  - reference: PMID:23974870
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;These variants were evaluated for both clinical severity and functional consequence, with 127 (80%) meeting both clinical and functional criteria consistent with disease.&#34;
    explanation: CFTR2 project provides systematic classification of CFTR variants for diagnostic interpretation.
- name: Newborn Screening
  description: &gt;-
    Population-based screening using immunoreactive trypsinogen (IRT) measured in
    dried blood spots collected at 24-48 hours of life. Elevated IRT is followed by
    either CFTR mutation panel or second IRT measurement. Positive screens require
    confirmatory sweat chloride testing.
  notes: Enables early diagnosis and treatment, improving outcomes. False negatives can occur with meconium ileus.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Most cases of CF are identified through newborn screening (NBS). There are also infants with positive NBS but inconclusive diagnostic testing; a small proportion of these infants may go on to develop CF.&#34;
    explanation: Clinical review confirms newborn screening as primary route to CF diagnosis and notes inconclusive cases.
- name: Nasal Potential Difference
  description: &gt;-
    Measurement of transepithelial voltage across nasal mucosa before and after
    perfusion with chloride-free solution and isoproterenol. Abnormal pattern
    (hyperpolarized baseline, absent chloride-free response) supports CFTR
    dysfunction. Used as ancillary diagnostic test in borderline cases.
  notes: Available only at specialized centers. Technically demanding.
  evidence:
  - reference: PMID:28129811
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Cystic fibrosis (CF), caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, continues to present diagnostic challenges.&#34;
    explanation: Advanced diagnostic methods like nasal potential difference are used for borderline cases.
- name: Intestinal Current Measurement
  description: &gt;-
    Ex vivo measurement of CFTR-mediated chloride transport in rectal biopsy tissue.
    Provides direct assessment of CFTR function. Used in research settings and for
    diagnosis in cases with inconclusive sweat chloride.
  notes: Primarily available in European centers. Highly sensitive and specific.
  evidence:
  - reference: PMID:28129811
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Cystic fibrosis (CF), caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, continues to present diagnostic challenges.&#34;
    explanation: Specialized diagnostic tests are used when standard methods are inconclusive.
environmental:
- name: Pseudomonas aeruginosa
  description: &gt;-
    The most important pathogen in CF lung disease. Initial acquisition of
    non-mucoid strains progresses to chronic infection with mucoid, alginate-producing
    phenotypes that form antibiotic-resistant biofilms. Chronic Pseudomonas infection
    is associated with accelerated decline in lung function and increased mortality.
    Early eradication protocols aim to delay chronic colonization.
  notes: Transition from non-mucoid to mucoid phenotype is a milestone event in CF.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Cystic fibrosis (CF) is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial airway infection.&#34;
    explanation: Chronic endobronchial infection including Pseudomonas is a defining characteristic of CF.
- name: Staphylococcus aureus
  description: &gt;-
    Often the first pathogen to colonize CF airways in infancy. Both
    methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains are
    common. MRSA infection is associated with worse lung function outcomes.
  notes: Most common respiratory pathogen in young CF children.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Progressive obstructive lung disease is driven by chronic bacterial infections including S. aureus.
- name: Burkholderia cepacia complex
  description: &gt;-
    Highly virulent group of gram-negative bacteria associated with rapid and
    sometimes fatal decline in lung function (cepacia syndrome). Patient-to-patient
    transmission necessitates strict infection control measures. B. cenocepacia
    (genomovar III) is the most virulent species and is a relative contraindication
    to lung transplantation at many centers.
  notes: Infection control and patient segregation are critical.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Progressive lung disease can be accelerated by virulent pathogens like Burkholderia.
- name: Non-tuberculous Mycobacteria
  description: &gt;-
    Mycobacterium abscessus complex and Mycobacterium avium complex are increasingly
    recognized in CF. M. abscessus is particularly concerning due to treatment
    resistance, potential for progressive lung disease, and may complicate lung
    transplant candidacy.
  notes: Screening sputum cultures recommended annually.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Progressive obstructive lung disease involves various pathogens including non-tuberculous mycobacteria.
- name: Aspergillus fumigatus
  description: &gt;-
    Fungal colonization of CF airways that can trigger allergic bronchopulmonary
    aspergillosis (ABPA), an IgE-mediated hypersensitivity response causing
    worsening airflow obstruction and central bronchiectasis.
  notes: ABPA requires treatment with systemic corticosteroids and antifungal agents.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility.&#34;
    explanation: Progressive obstructive lung disease includes complications from fungal colonization.
- name: Tobacco Smoke Exposure
  description: &gt;-
    Both active and passive tobacco smoke exposure accelerates lung function
    decline in CF patients. Environmental tobacco smoke is a significant modifiable
    risk factor, especially in children.
  notes: Strict avoidance counseling is part of standard CF care.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific interdisciplinary care centers.&#34;
    explanation: Evidence-based guidelines include avoidance of environmental risk factors like tobacco smoke.
- name: Air Pollution
  description: &gt;-
    Ambient air pollution (particulate matter, ozone, nitrogen dioxide) is
    associated with increased pulmonary exacerbation rates and accelerated lung
    function decline in CF.
  notes: Epidemiologic association; exposure minimization recommended.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific interdisciplinary care centers.&#34;
    explanation: Optimization of pulmonary health includes minimizing environmental exposures.
treatments:
- name: Elexacaftor-Tezacaftor-Ivacaftor (Trikafta/Kaftrio)
  description: &gt;-
    Triple combination CFTR modulator therapy containing two correctors
    (elexacaftor, tezacaftor) that improve F508del-CFTR folding and trafficking
    to the cell surface, plus a potentiator (ivacaftor) that increases channel
    open probability. Approved for patients aged 2+ years with at least one
    F508del allele, covering approximately 90% of CF patients. Produces dramatic
    improvements in lung function, nutritional status, and quality of life.
  evidence:
  - reference: PMID:31697873
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Elexacaftor-tezacaftor-ivacaftor, relative to placebo, resulted in a percentage of predicted FEV1 that was 13.8 points higher at 4 weeks and 14.3 points higher through 24 weeks, a rate of pulmonary exacerbations that was 63% lower&#34;
    explanation: Phase 3 RCT demonstrates significant improvement in lung function and 63% reduction in pulmonary exacerbations with Trikafta.
  - reference: PMID:31697873
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;a respiratory domain score on the Cystic Fibrosis Questionnaire-Revised...that was 20.2 points higher, and a sweat chloride concentration that was 41.8 mmol per liter lower&#34;
    explanation: Trikafta also improves quality of life scores and reduces sweat chloride, a biomarker of CFTR function.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Ivacaftor (Kalydeco)
  description: &gt;-
    CFTR potentiator that increases the channel open probability of CFTR protein
    at the cell surface. First approved CFTR modulator, initially for G551D
    mutation and subsequently expanded to other gating mutations. As monotherapy,
    effective only for mutations where CFTR reaches the cell surface
    (Class III, IV, V mutations).
  evidence:
  - reference: PMID:22047557
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The change from baseline through week 24 in the percent of predicted FEV(1) was greater by 10.6 percentage points in the ivacaftor group than in the placebo group (P&lt;0.001).&#34;
    explanation: Landmark Phase 3 trial demonstrating sustained lung function improvement with ivacaftor in G551D patients.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Airway Clearance Therapy
  description: &gt;-
    Chest physiotherapy techniques to mobilize and clear airway secretions.
    Includes manual chest percussion and postural drainage, oscillating positive
    expiratory pressure devices (e.g., Flutter, Acapella), high-frequency chest
    wall oscillation vests, autogenic drainage, and regular exercise. Performed
    at least twice daily.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific interdisciplinary care centers.&#34;
    explanation: Evidence-based guidelines for pulmonary health include airway clearance therapies.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
- name: Dornase Alfa (Pulmozyme)
  description: &gt;-
    Inhaled recombinant human DNase that cleaves extracellular DNA released from
    necrotic neutrophils in CF sputum, reducing mucus viscosity and improving
    airway clearance. Recommended for daily use in most CF patients.
  evidence:
  - reference: PMID:8874241
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Dornase alfa improved the mean percent change in FEV1 from baseline by 9.4% compared with 2.1% for placebo (p &lt; 0.001).&#34;
    explanation: Randomized controlled trial demonstrates significant improvement in lung function with dornase alfa.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Hypertonic Saline (7%)
  description: &gt;-
    Inhaled nebulized hypertonic saline that osmotically draws water onto the
    airway surface, rehydrating the periciliary layer and improving mucociliary
    clearance. Used as adjunctive therapy to improve mucus mobilization.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific interdisciplinary care centers.&#34;
    explanation: Evidence-based therapies for pulmonary health include mucolytic agents like hypertonic saline.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Inhaled Antibiotics
  description: &gt;-
    Chronic suppressive inhaled antibiotic therapy for patients with chronic
    Pseudomonas aeruginosa infection. Inhaled tobramycin (alternating months)
    and inhaled aztreonam lysine are most commonly used. Reduces bacterial
    density, decreases pulmonary exacerbations, and preserves lung function.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific interdisciplinary care centers.&#34;
    explanation: Improved survival reflects evidence-based treatments including inhaled antibiotics for chronic infection.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Systemic Antibiotics
  description: &gt;-
    Oral and intravenous antibiotics for acute pulmonary exacerbations and
    chronic suppressive therapy. Azithromycin is used chronically for its
    anti-inflammatory and anti-Pseudomonal properties. IV antibiotic courses
    (typically 14-21 days) target specific pathogens identified on sputum culture.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific interdisciplinary care centers.&#34;
    explanation: Evidence-based care includes systemic antibiotics for treating pulmonary exacerbations.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Pancreatic Enzyme Replacement Therapy (PERT)
  description: &gt;-
    Oral pancreatic enzyme supplements (lipase, protease, amylase) taken with
    all meals and snacks to replace deficient endogenous enzymes. Dosing is
    individualized based on fat intake and symptoms. Essential for maintaining
    adequate nutrition in pancreatic-insufficient patients.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific interdisciplinary care centers.&#34;
    explanation: Optimization of nutritional health includes pancreatic enzyme replacement therapy.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Nutritional Support
  description: &gt;-
    High-calorie, high-fat diet with fat-soluble vitamin supplementation (A, D, E, K)
    and sodium chloride supplementation. CF patients have increased caloric
    requirements (120-150% of normal) due to malabsorption, chronic infection,
    and increased work of breathing. Enteral tube feeding may be needed for
    patients unable to maintain adequate weight.
  evidence:
  - reference: PMID:33526571
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific interdisciplinary care centers.&#34;
    explanation: Evidence-based guidelines emphasize optimization of nutritional health for CF patients.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
- name: Insulin Therapy for CFRD
  description: &gt;-
    Insulin is the recommended treatment for CF-related diabetes. Oral
    hypoglycemic agents are generally not recommended as primary therapy
    due to the predominantly insulin-deficient pathophysiology. Insulin
    improves nutritional status and lung function in addition to
    glycemic control.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility.&#34;
    explanation: CF-related diabetes is an established complication requiring insulin therapy.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Ursodeoxycholic Acid
  description: &gt;-
    Hydrophilic bile acid used to improve bile flow and potentially slow
    progression of CF liver disease. Commonly prescribed for patients with
    elevated liver enzymes or evidence of focal biliary cirrhosis, though
    evidence for long-term clinical benefit is limited.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Other complications include sinusitis, diabetes mellitus, bowel obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility.&#34;
    explanation: Hepatobiliary disease in CF is treated with agents like ursodeoxycholic acid.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Lung Transplantation
  description: &gt;-
    Bilateral lung transplantation is offered for end-stage CF lung disease
    when predicted survival without transplant is limited (typically FEV1 &lt;30%
    predicted with rapid decline). Five-year survival after transplant is
    approximately 50-60%. CF lung disease does not recur in the transplanted lungs,
    but immunosuppression-related complications and chronic rejection (bronchiolitis
    obliterans syndrome) limit long-term outcomes.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;This latter feature results in progressive bronchiectasis and ultimately respiratory failure, which is the leading cause of death in patients with CF.&#34;
    explanation: Respiratory failure as the leading cause of death necessitates lung transplantation for end-stage disease.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
- name: Genetic Counseling
  description: &gt;-
    Counseling for patients and families regarding autosomal recessive
    inheritance, carrier testing for at-risk relatives, prenatal diagnosis
    options, and reproductive planning. Carrier frequency is approximately
    1 in 25 in European-descent populations.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
clinical_trials:
- name: NCT03525444
  phase: PHASE_III
  status: COMPLETED
  description: &gt;-
    Phase 3, randomized, double-blind, placebo-controlled trial evaluating
    elexacaftor-tezacaftor-ivacaftor in patients aged 12+ with cystic fibrosis
    heterozygous for F508del and a minimal-function CFTR mutation. This landmark
    trial led to FDA approval of Trikafta.
  target_phenotypes:
  - preferred_term: Bronchiectasis
    term:
      id: HP:0002110
      label: Bronchiectasis
  - preferred_term: Recurrent respiratory infections
    term:
      id: HP:0002205
      label: Recurrent respiratory infections
  evidence:
  - reference: PMID:31697873
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Elexacaftor-tezacaftor-ivacaftor was efficacious in patients with cystic fibrosis with Phe508del-minimal function genotypes, in whom previous CFTR modulator regimens were ineffective.&#34;
    explanation: This Phase 3 trial established efficacy of Trikafta for CF patients with one F508del allele plus a minimal-function mutation.
has_subtypes:
# CFTR mutation class subtypes
- name: Class I - No Protein Production
  classification: mutation_class
  description: &gt;-
    Nonsense mutations, frameshift mutations, and canonical splice site mutations
    that result in premature termination codons and no functional CFTR protein
    production due to mRNA degradation via nonsense-mediated decay. Examples include
    G542X, W1282X, R553X, and 621+1G&gt;T. Class I mutations cause severe disease
    with pancreatic insufficiency.
  children:
  - G542X
  - W1282X
  - R553X
  evidence:
  - reference: PMID:27053340
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;An effective, although not yet entirely corrective, treatment is available for patients with class III mutations, and a treatment with modest effectiveness is available for patients who are homozygous for Phe508del, albeit at a very high cost.&#34;
    explanation: Review discusses CFTR mutation classes and their therapeutic implications, establishing the classification system.
- name: Class II - Processing/Trafficking Defect
  classification: mutation_class
  description: &gt;-
    Mutations causing CFTR protein misfolding, endoplasmic reticulum retention, and
    proteasomal degradation. The most important example is F508del, present in nearly
    90% of CF patients. Misfolded protein is recognized by ER quality control and
    targeted for ubiquitin-proteasome degradation, resulting in minimal CFTR at the
    cell surface. Corrector drugs (lumacaftor, tezacaftor, elexacaftor) partially
    rescue F508del trafficking.
  children:
  - F508del
  - N1303K
  - I507del
  evidence:
  - reference: PMID:31697873
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;nearly 90% of patients have at least one copy of the Phe508del CFTR mutation&#34;
    explanation: Confirms the high prevalence of the prototypical Class II mutation F508del.
- name: Class III - Gating Defect
  classification: mutation_class
  description: &gt;-
    CFTR protein reaches the cell surface normally but channel gating is severely
    impaired, resulting in very low open probability. The prototypical example is
    G551D. Potentiator drugs (ivacaftor) increase channel open probability and
    produce dramatic clinical benefit.
  children:
  - G551D
  - S549N
  - G1244E
  evidence:
  - reference: PMID:22047557
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The change from baseline through week 24 in the percent of predicted FEV(1) was greater by 10.6 percentage points in the ivacaftor group than in the placebo group (P&lt;0.001).&#34;
    explanation: Ivacaftor trial in G551D patients demonstrates therapeutic targeting of gating mutations.
- name: Class IV - Conductance Defect
  classification: mutation_class
  description: &gt;-
    CFTR reaches the cell surface and channel opens, but chloride conductance
    through the channel pore is reduced. Typically associated with milder phenotype
    and pancreatic sufficiency. Examples include R117H, R334W, and R347P.
  children:
  - R117H
  - R334W
  - R347P
  evidence:
  - reference: PMID:27053340
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;An effective, although not yet entirely corrective, treatment is available for patients with class III mutations, and a treatment with modest effectiveness is available for patients who are homozygous for Phe508del, albeit at a very high cost.&#34;
    explanation: Review describes mutation class-specific treatments, including Class IV conductance defects.
- name: Class V - Reduced Quantity
  classification: mutation_class
  description: &gt;-
    Mutations that reduce the amount of normal CFTR protein produced, such as
    alternative splice site mutations that produce some normal transcript alongside
    aberrant transcript. Typically associated with milder phenotype and pancreatic
    sufficiency. Examples include 3849+10kbC&gt;T and A455E.
  children:
  - 3849+10kbC&gt;T
  - A455E
  evidence:
  - reference: PMID:27053340
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;An effective, although not yet entirely corrective, treatment is available for patients with class III mutations, and a treatment with modest effectiveness is available for patients who are homozygous for Phe508del, albeit at a very high cost.&#34;
    explanation: Review discusses the classification system and mutation classes.
- name: Class VI - Decreased Stability
  classification: mutation_class
  description: &gt;-
    CFTR protein reaches the cell surface and functions but has accelerated
    turnover and reduced plasma membrane stability. Rescued F508del protein
    (after corrector therapy) exhibits this additional defect, necessitating
    combination therapy with correctors and potentiators.
  evidence:
  - reference: PMID:37699417
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;With the 2019 breakthrough in the development of highly effective modulator therapy providing unprecedented clinical benefits for over 90% of patients with cystic fibrosis who are genetically eligible for treatment, this rare disease has become a front runner of transformative molecular therapy.&#34;
    explanation: Review discusses CFTR modulator therapy addressing multiple defects including decreased stability.
# Clinical phenotype subtypes
- name: Classic Cystic Fibrosis
  classification: clinical_phenotype
  description: &gt;-
    Severe disease phenotype with two severe CFTR mutations, pancreatic insufficiency,
    progressive bronchiectasis, elevated sweat chloride (&gt;=60 mmol/L), and male
    infertility due to CBAVD. Represents the majority of CF patients.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Cystic fibrosis (CF) is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial airway infection.&#34;
    explanation: Clinical review describes the classic CF phenotype of pancreatic insufficiency and chronic airway infection.
- name: Atypical (Non-Classic) Cystic Fibrosis
  classification: clinical_phenotype
  description: &gt;-
    Milder disease phenotype, often with at least one CFTR mutation conferring
    residual function (Class IV, V). May present with pancreatic sufficiency,
    milder lung disease, borderline or normal sweat chloride, and later age of
    diagnosis. Some patients are not diagnosed until adulthood.
  evidence:
  - reference: PMID:33178516
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Cystic fibrosis (CF) is an autosomal recessive, multi-organ disorder found predominantly among Caucasians.&#34;
    explanation: Case report of atypical CF diagnosis at age 57, illustrating the spectrum of disease severity and late diagnosis in non-classic presentations.
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;There are also infants with positive NBS but inconclusive diagnostic testing; a small proportion of these infants may go on to develop CF.&#34;
    explanation: Some individuals with inconclusive diagnostic testing have milder, atypical presentations that may evolve over time.
- name: CFTR-Related Metabolic Syndrome (CRMS) / CF Screen Positive Inconclusive Diagnosis (CFSPID)
  classification: clinical_phenotype
  description: &gt;-
    Designation for infants identified by newborn screening who do not meet
    diagnostic criteria for CF but have some evidence of CFTR dysfunction.
    Defined as either intermediate sweat chloride (30-59 mmol/L) with fewer than
    two CF-causing CFTR mutations, or normal sweat chloride (&lt;30 mmol/L) with
    two CFTR mutations of which at least one has unclear clinical significance.
    A small proportion may evolve to a CF diagnosis over time. Requires longitudinal
    monitoring.
  evidence:
  - reference: PMID:30986316
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;There are also infants with positive NBS but inconclusive diagnostic testing; a small proportion of these infants may go on to develop CF.&#34;
    explanation: Clinical review describes the scenario of inconclusive CF diagnosis after positive newborn screening.
  - reference: PMID:28129811
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Cystic fibrosis (CF), caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, continues to present diagnostic challenges.&#34;
    explanation: CF Foundation guidelines address diagnostic challenges including CRMS/CFSPID designation.
# CFTR-related disorders
- name: Congenital Bilateral Absence of the Vas Deferens (CBAVD)
  classification: CFTR_related_disorder
  description: &gt;-
    Isolated congenital bilateral absence of the vas deferens causing obstructive
    azoospermia and male infertility, without other features of classic CF. Found
    in approximately 1-2% of infertile males. Most affected men carry at least
    one CFTR mutation, often including the 5T poly-T variant or R117H. Sweat
    chloride is typically normal or borderline. Lung and pancreatic function
    are preserved.
- name: CFTR-Related Pancreatitis
  classification: CFTR_related_disorder
  description: &gt;-
    Recurrent acute or chronic pancreatitis in individuals carrying one or two
    CFTR mutations with residual function, without meeting diagnostic criteria
    for CF. CFTR dysfunction impairs bicarbonate secretion in pancreatic ducts,
    predisposing to ductal obstruction and pancreatitis. Sweat chloride is
    typically normal or borderline.
- name: CFTR-Related Disseminated Bronchiectasis
  classification: CFTR_related_disorder
  description: &gt;-
    Diffuse bronchiectasis in individuals carrying CFTR mutations who do not
    meet diagnostic criteria for CF. Sweat chloride may be normal or borderline.
    Represents the milder end of the CFTR dysfunction spectrum affecting
    the airways.
notes: &gt;-
  Cystic fibrosis care has been transformed by CFTR modulator therapy, particularly
  elexacaftor-tezacaftor-ivacaftor (Trikafta), which provides substantial clinical
  benefit for approximately 90% of CF patients. Median survival has increased from
  early childhood death to beyond 40 years, with further improvements expected.
  Multidisciplinary care at specialized CF centers remains essential, encompassing
  pulmonary, nutritional, endocrine, hepatic, and psychosocial aspects. The CF
  Foundation accredits specialized care centers and maintains registries that drive
  quality improvement. Remaining therapeutic challenges include patients with
  nonsense mutations (Class I) not responsive to current modulators, established
  lung damage in older patients, and long-term effects of CFTR modulator therapy.
  Gene therapy and mRNA-based approaches are under active investigation for patients
  with mutations not amenable to small molecule modulation.
disease_term:
  preferred_term: cystic fibrosis
  term:
    id: MONDO:0009061
    label: cystic fibrosis
classifications:
  harrisons_chapter:
  - classification_value: respiratory system disorder
  - classification_value: hereditary disease
datasets:
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Cystic_Fibrosis.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>